

| EU Local Number | EY Category | Report Type | Primary Source Qualification | Primary Source Country | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Leading Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|-------------------|-------------|-------------|------------------------------|----------------------------|----------------------|--------------------|---------------|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | | | | | | | | | Coma scale abnormal (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Confusional state (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Death (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Headache (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Hydrocephalus (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Intraventricular haemorrhage (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Lethargy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Malaise (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Subarachnoid haemorrhage (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Thrombocytopenia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling), Vomiting (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling) | | | |
| EU-EC-10010567800 | 0411/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Abdominal pain upper (n/a - Unknown - Life Threatening), Chronic kidney disease (n/a - Not Recovered/Not Resolved - Life Threatening), Death (n/a - Unknown - Life Threatening) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | INFLUENZA VIRUS(C) (n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10010568127 | 0311/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | Not Specified | Not Specified | Female | Urinary incontinence (n/a - Unknown - Life Threatening) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010563451 | 0111/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Anaemia (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Dyspnoea (n/a - Fatal - Results in Death), Hypotensive to stimuli (n/a - Fatal - Results in Death), Lethargy (n/a - Fatal - Results in Death), Sepsis (n/a - Fatal - Results in Death, Other Medically Important Condition) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - Not applicable - 1(d) - 10P) - intramuscular | | ICSR |
| EU-EC-10010483095 | 2910/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Abdominal pain upper (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Headache (n/a - Unknown - Other Medically Important Condition), Subarachnoid haemorrhage (n/a - Unknown - Life Threatening, Other Medically Important Condition), Vomiting (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010480504 | 2710/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Cognitive disorder (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Pericarditis (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Pyrexia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010481851 | 2710/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death), Dizziness (n/a - Unknown - Other Medically Important Condition), Vertigo (n/a - Unknown - Other Medically Important Condition) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - 10P) - intramuscular | ACCENOQUIMAR(C) (n/a - n/a - [n/a - n/a - n/a]), BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE (C) (n/a - n/a - [n/a - n/a - n/a]), CALCIUM CARBONATE (C) (n/a - n/a - [n/a - n/a - n/a]), COLECALCIFEROL (C) (n/a - n/a - [n/a - n/a - n/a]), DOXAZOSIN, DOXAZOSIN MESILATE (C) (n/a - n/a - [n/a - n/a - n/a]), FUROSEMIDE, FUROSEMIDE SODIUM (C) (n/a - n/a - [n/a - n/a - n/a]), HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE HYDROGEN SUCCINATE (C) (n/a - n/a - [n/a - n/a - n/a]), LEVOTHYROIDINE, LEVOTHYROIDINE SODIUM (C) (n/a - n/a - [n/a - n/a - n/a]), METFORMIN HYDROCHLORIDE (C) (n/a - n/a - [n/a - n/a - n/a]), METHILDIOXIN (C) (n/a - n/a - [n/a - n/a - n/a]), MICRONISED SPIRONOLACTONE, POTASSIUM CANRENATE, SPIRONOLACTONE, SPIRONOLACTONE BPF (C) (n/a - n/a - [n/a - n/a - n/a]), PANTOPRAZOLE, PANTOPRAZOLE SODIUM SESQUIHYDRATE (C) (n/a - n/a - [n/a - n/a - n/a]), RAMIPRIL (C) (n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10010338668 | 1510/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - 10P) - intramuscular | | ICSR |
| EU-EC-10010281704 | 0810/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | COVID-19 (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular) | MALODIPINE, MALODIPINE BESILATE (C) (n/a - Unknown - [n/a - n/a - n/a]), METOPROLOL TARTRATE (C) (n/a - Unknown - [n/a - n/a - n/a]), BISOPROLOL FUMARATE (C) (n/a - Unknown - [n/a - n/a - n/a]), LORANTANOL, LORANTANOL (C) (n/a - Unknown - [n/a - n/a - n/a]), LUSARTAN, METASULAM (C) (n/a - Unknown - [n/a - n/a - n/a]), SUMATRIPTAN (C) (n/a - Unknown - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10010236498 | 0610/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular) | | ICSR |
| EU-EC-10010232728 | 0510/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - 5mL - intramuscular) | | ICSR |
| EU-EC-10010239242 | 0610/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - 5mL - intramuscular) | | ICSR |
| EU-EC-10010217729 | 0510/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Acute thrombosis (n/a - Unknown - Caused/Prolonged Hospitalisation), Bradycardia (n/a - Unknown - Caused/Prolonged Hospitalisation), Cardiac arrest (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Chest pain (n/a - Unknown - Caused/Prolonged Hospitalisation), Circulatory collapse (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Confusional state (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Deep vein thrombosis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Dyspnoea (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation), Fatigue (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Headache (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Hypertension (n/a - Unknown - Caused/Prolonged Hospitalisation), Myocardial infarction (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation), Myocardial ischaemia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Pain in extremity (n/a - Unknown - Caused/Prolonged Hospitalisation), Peripheral artery thrombosis (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Peripheral oedema (n/a - Unknown - Caused/Prolonged Hospitalisation), Peripheral ischaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Pulmonary embolism (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Pulseless electrical activity (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Renal infarct (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Splenic infarction (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Thrombocytopenia (n/a - Unknown - Caused/Prolonged Hospitalisation), Ventricular arrhythmias (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010195552 | 0110/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death), Asthma (n/a - Not Recovered/Not Resolved -) Decreased appetite (n/a - Not Recovered/Not Resolved -) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - COVID-19 immunisation - Not applicable - 1(d) - 10P) - intramuscular | | ICSR |
| EU-EC-10010181859 | 2909/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Cerebrovascular accident (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - n/a - Not applicable - 1(d) - n/a - intramuscular) | | ICSR |
| EU-EC-10010164688 | 2909/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Not Specified | Thrombosis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010154707 | 2609/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010122751 | 2409/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Adult | Male | Acute disseminated encephalomyelitis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death), Gait mobility (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Hyperhidrosis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Hypertension (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Pain (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Pyrexia (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Urinary retention (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - 5mL - intramuscular] | [MESALAZINE] (C - Colitis ulcerosa - Unknown - [n/a - 2g - n/a]), [VALSARTAN] (C - Hypertension - Unknown - [n/a - 160mg - Oral]) | ICSR |
| EU-EC-1001012306 | 2409/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010083474 | 2209/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Female | Blood glucose abnormal (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Diarrhoea (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Headache (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Hepatic function abnormal (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Paralysis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Vomiting (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10010097954 | 2209/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10010088622 | 2209/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010080893 | 2109/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Asteroidosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Atelectasis (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Cardiotoxicity (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Cerebrovascular accident (n/a - Recovered/Resolved With Sequela - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Recovered/Resolved - Other Medically Important Condition), Gangrene (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - 10P) - intramuscular] | [AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [FOGNOPIRIL SODIUM] (C - Hypertension - Unknown - [n/a - n/a - Oral]), [FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [GLICLAZIDE] (C - n/a - n/a - [n/a - 60mg - n/a]), [INSULIN LISPRO] (C - n/a - n/a - [n/a - n/a - n/a]), [METOPROLOL, METOPROLOL TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]), [PANTOPRAZOLE SODIUM SESQUIHYDRATE] (C - n/a - n/a - [n/a - n/a - n/a]), [POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [ZEMFRAZOLE] (C - Gastroesophageal reflux disease - Dose not changed - [n/a - 20mg - Oral]), [THEOPHYLLINE] (C - Chronic obstructive pulmonary disease - Dose not changed - [n/a - 200mg - Oral]), [TIDIOPIRUM] (C - Chronic obstructive pulmonary disease - Dose not changed - [n/a - 15mg - Respiratory Inhalator]) | ICSR |
| EU-EC-10010062753 | 2109/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Asymptomatic COVID-19 (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - Not applicable - 1(d) - 5mL - intramuscular) | | ICSR |
| EU-EC-10010084950 | 2109/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | COVID-19 (n/a - Recovered/Resolved -), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Eating disorder (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010081029 | 2009/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Pulmonary embolism (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010081633 | 1509/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Dyspnoea (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10010011320 | 1509/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | Cerebral venous sinus thrombosis (n/a - Unknown - Disabling), Death (n/a - Fatal - Results in Death), Haemorrhagic infarction (n/a - Unknown - Disabling), Thrombocytopenia (n/a - Unknown - Disabling) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009981108 | 1409/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009989556 | 1409/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), No adverse event (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009985547 | 1409/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10009984329 | 1309/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Not Specified | Dizziness (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009989999 | 1009/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009981212 | 1009/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Adult | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009983522 | 1009/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - n/a - [n/a - n/a - intramuscular]) | | ICSR |
| EU-EC-10009989738 | 0909/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COMBINATY (COMBINERAN) (S - Immunisation - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10009983954 | 0809/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death), Diarrhoea (n/a - Unknown -) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | [ACETYLSALICYLIC ACID, D,L-LYSINE ACETYLSALICYLATE] (C - Product used for unknown indication - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10009983628 | 0809/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Cerebrovascular accident (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - n/a - Not applicable - 1(d) - n/a - intramuscular) | | ICSR |
| EU-EC-10009981918 | 0709/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Asthma (n/a - Unknown - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009982504 | 0709/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10009984622 | 0609/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death), Fatigue (n/a - Unknown -), Rash (n/a - Unknown -), Vomiting (n/a - Unknown -) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10009896396 | 0409/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Not Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10009894916 | 0109/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | COVID-19 (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19)) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10009895441 | 0109/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Adult | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - 1(d) - n/a - intramuscular] | | ICSR |
| EU-EC-10008888605 | 0109/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Embolism (n/a - Fatal - Results in Death), Atherosclerosis (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Atherosclerosis coronary artery (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), COVID-19 (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Cough (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Excessive (n/a - Fatal - Results in Death, Life Threat | | | |

| EU Local Number | EV Category/Report Date | Report Type | Primary Source/Qualification | Primary Source/Country for Regulatory Purposes | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Patient Onset | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Interacting Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|-------------------|-------------------------|-------------|------------------------------|------------------------------------------------|----------------------|--------------------|---------------|----------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | | | | | | | | | | Lung infiltration (Ad - Fatal - Results in Death, Life Threatening, CausedProlonged Hospitalisation), Renal anergy (Ad - Fatal - Results in Death, Life Threatening, CausedProlonged Hospitalisation) | | DILTIAZEM DILTIAZEM HYDROCHLORIDE (C - n/a - Unknown - [n/a - 200mg - n/a]), DRIED FERROUS SULFATE, FERROUS SULFATE, FERROUS SULFATE HYDRATE, FERROUS SULPHATE SESQUHYDRATE (C - n/a - Unknown - [n/a - 80mg - n/a]), [FLUTAMIDE] (C - n/a - Unknown - [n/a - 500mg - n/a]), [FUROSEMIDE, FUROSEMIDE SODIUM] (C - n/a - Unknown - [n/a - 20mg - n/a]), [MAGNESIUM CARBONATE HEAVY, CALCIUM ACETATE] (C - n/a - Unknown - [n/a - 10DF - n/a]), [TRIPTORELIN, TRIPTORELIN ACETATE, TRIPTORELIN PAMOTATE] (C - n/a - Unknown - [n/a - 15DF - n/a]), [ACETYSALICYLIC ACID, ACETYSALICYLIC ACID IN ELIXIR, ASPIRIN BP] (C - n/a - n/a - [n/a - n/a - n/a]), [BECLOMETHASONE DIPROPIONATE, FORMOTEROL FLUMARATE DIHYDRATE, FORMOTEROL FLUMARATE DIHYDRATE, BECLOMETHASONE DIPROPIONATE ANHYDRIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL, HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [GLYCERYL TRINITRATE] (C - n/a - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]), [QUININE] (C - n/a - n/a - [n/a - n/a - n/a]), [SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]), [FAPENTADOL] (C - n/a - n/a - [n/a - n/a - n/a]), [SALFURIDOL] (C - n/a - Unknown - [n/a - n/a - n/a]), [ATELOLOL, ATELOLOL BP] (C - n/a - Unknown - [n/a - n/a - n/a]), [LERCANIDIPINE HYDROCHLORIDE] (C - n/a - Unknown - [n/a - n/a - n/a]) | |
| EU-EC-1000825148 | 30/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Cellulitis (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-100082819 | 30/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Cardiovascular disorder (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death), Myocardial ischaemia (n/a - Fatal - Results in Death), Peripheral artery thrombosis (n/a - Fatal - Results in Death), Renal disorder (n/a - Fatal - Results in Death), Shock (n/a - Fatal - Results in Death), Thrombocytopenia (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-100082209 | 28/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | COVID-19 immunisation (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition), Cephalalgia (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition), Hypertension (n/a - Unknown - Life Threatening, Other Medically Important Condition), Hypertension (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition), Oxygen saturation decreased (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition), Peripheral oedema (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition), Sepsis (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition), Tachycardia (n/a - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100082260 | 28/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, CausedProlonged Hospitalisation), Dyspnoea (n/a - Not Recovered/Not Resolved - Results in Death, CausedProlonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | [ACETYSALICYLIC ACID] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]), [ATORVASTATIN] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]), [BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL, HEMIFUMARATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]), [BUPROPION, BUPROPION HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]), [ENALAPRIL, ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - n/a - n/a]), [INFLUENZA VIRUS] (C - Influenza immunisation - n/a - [n/a - n/a - n/a]), [ISOSORBIDE MONONITRATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]), [METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000811963 | 27/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, CausedProlonged Hospitalisation), Headache (n/a - Fatal - Results in Death, CausedProlonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000814791 | 27/08/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Malaria (n/a - Unknown - CausedProlonged Hospitalisation), Cerebral haemorrhage (n/a - Unknown - CausedProlonged Hospitalisation), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000818301 | 27/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, CausedProlonged Hospitalisation), Diarrhoea (n/a - Unknown - CausedProlonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000830236 | 30/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Pan (n/a - Unknown - CausedProlonged Hospitalisation), Pulmonary hypertension (n/a - Unknown - Life Threatening, CausedProlonged Hospitalisation, Other Medically Important Condition), Septic shock (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | [SOURIS [CULDESIMAM]] (C - Apyloid haemolytic uraemic syndrome - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000789534 | 24/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Cardiac arrest (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - n/a - [n/a - n/a - n/a]) | FLAVIX [CLOPIDOGREL, CLOPIDOGREL HYDROGEN SULFATE] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - n/a - n/a]), [ACETYSALICYLIC ACID] (C - Ischaemic heart disease prophylaxis - n/a - [n/a - n/a - n/a]), [FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]), [ISOSORBIDE DINITRATE] (C - Chest pain - n/a - [n/a - n/a - n/a - Respiratory (inhalation)], [MAGNESIUM, MAGNESIUM HYDROXIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [METFORMIN, METFORMIN HYDROCHLORIDE] (C - Type 2 diabetes mellitus - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]), [POTASSIUM CHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000772306 | 24/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Cyanosis (n/a - Fatal - Results in Death, Life Threatening), Death (n/a - Fatal - Results in Death, Life Threatening), Dyspnoea (n/a - Fatal - Results in Death, Life Threatening), Lethargy (n/a - Unknown -), Peripheral oedema (n/a - Fatal - Results in Death, Life Threatening), Pyrexia (n/a - Unknown -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - Not applicable - [n/a - 10DF - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000783271 | 23/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000782734 | 23/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | No | Death (n/a - Fatal - Results in Death), Dizziness (n/a - Not Recovered/Not Resolved -), Palpitations (n/a - Not Recovered/Not Resolved -), Parosmia (n/a - Not Recovered/Not Resolved -), Sinus disorder (n/a - Unknown -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000786547 | 23/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000793368 | 21/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Not applicable - [n/a - n/a - n/a]) | INSULIN HUMAN [INSULIN HUMAN] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000793258 | 21/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | No | Death (n/a - Fatal - Results in Death), Myocardial infarction (n/a - Unknown - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000793762 | 21/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (Ad - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000742330 | 20/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Cerebrovascular accident (T1 - Recovering/Resolving - Life Threatening, CausedProlonged Hospitalisation, Other Medically Important Condition), Constipation abnormal (n/a - Unknown -), Death (n/a - Fatal - Results in Death), Dysarthria (n/a - Unknown -), Feeling abnormal (n/a - Unknown -), Gait disturbance (n/a - Unknown -), Hemiplegia (n/a - Unknown - Other Medically Important Condition), Muscular weakness (n/a - Unknown -), Parosmia (n/a - Unknown -), Speech disorder (n/a - Unknown -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | CLOPIDOGREL [CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - n/a - n/a -), [CYANOCOBALAMIN] (C - n/a - n/a -) | ICSR |
| EU-EC-1000747699 | 20/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 19-64 Years | Not Specified | Male | No | Thrombosis (T1 - Recovering/Resolving - Life Threatening, CausedProlonged Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Drinking (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Gaze palsy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Seizure (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - Not applicable - [n/a - 10DF - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000748544 | 20/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Cough (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000748956 | 20/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Unresponsive to stimuli (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Decreased appetite (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - Not applicable - [n/a - 10DF - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000749428 | 20/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Fatal - Results in Death), Hypophagia (n/a - Fatal - Results in Death), Loss of consciousness (n/a - Fatal - Results in Death), Pneumonia (n/a - Fatal - Results in Death), Unresponsive to stimuli (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - Not applicable - [n/a - 10DF - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000721880 | 18/08/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Myocardial infarction (n/a - Unknown - CausedProlonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100078168 | 17/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - n/a - [n/a - 10DF - n/a]) | Not reported | ICSR |
| EU-EC-1000798504 | 17/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Myocardial infarction (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000710578 | 17/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Elderly | Male | No | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown -) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - n/a - [n/a - 10DF - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000969643 | 16/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Angina pectoris (n/a - Fatal - Results in Death, CausedProlonged Hospitalisation), Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10009687983 | 14/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (T1 - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000968163 | 14/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | COVID-19 (T1 - Not Recovered/Not Resolved - Results in Death), Death (2527a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000867735 | 13/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Alpha (n/a - Fatal - Results in Death), Blood nitrogen increased (n/a - Fatal - Results in Death), Brain oedema (n/a - Fatal - Results in Death), C-reactive protein increased (n/a - Fatal - Results in Death), Cerebral haemorrhage (n/a - Fatal - Results in Death), Cerebral ischaemia (n/a - Fatal - Results in Death), Coagulopathy (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Disorientation (n/a - Fatal - Results in Death), Epilepsy (n/a - Fatal - Results in Death), Fatigue (n/a - Fatal - Results in Death), Fibrin D dimer increased (n/a - Fatal - Results in Death), Headache (n/a - Fatal - Results in Death), Hepatitis-induced thrombocytopenia test positive (n/a - Fatal - Results in Death), Limb discomfort (n/a - Fatal - Results in Death), Malaise (n/a - Fatal - Results in Death), Myalgia (n/a - Fatal - Results in Death), Respiration abnormal (n/a - Fatal - Results in Death), Retrograde amnesia (n/a - Fatal - Results in Death), Seizure (n/a - Fatal - Results in Death), Snoring (n/a - Fatal - Results in Death), Somnolence (n/a - Fatal - Results in Death), Superior sagittal sinus thrombosis (n/a - Fatal - Results in Death), Thrombocytopenia (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | [ANHYDROUS, LEVOTHYROXINE SODIUM] (C - n/a - Unknown - [n/a - n/a - n/a]), [BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL, HEMIFUMARATE] (C - n/a - Unknown - [n/a - n/a - n/a]), [CLOTIAZEPAM] (C - n/a - Unknown - [n/a - n/a - n/a]), [FENOTEROL, HYDROBROMIDE, IPRATROPIUM BROMIDE, FENOTEROL, HYDROBROMIDE, IPRATROPIUM BROMIDE MONOHYDRATE] (C - n/a - Unknown - [n/a - n/a - n/a]), [METHYLPREDNISOLONE] (C - n/a - Unknown - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000861486 | 12/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Coagulopathy (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Other Medically Important Condition), Night sweats (n/a - Unknown - Other Medically Important Condition), Pyrexia (n/a - Unknown - Other Medically Important Condition), Not blood cell count increased (n/a - Unknown - Other Medically Important Condition), White blood cell count increased (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000867256 | 12/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Death (D2 - Fatal - Results in Death), Fatigue (D1 - Fatal - Results in Death), Pain (D2 - Fatal - Results in Death), Pneumonia (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-1000861117 | 11/08/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Pyrexia (D1 - Fatal - Results in Death), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Myocardial infarction (n/a - Fatal - Results in Death, Other Medically Important Condition) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - Immunisation - n/a - [n/a - 10DF - Intramuscular]) | [COPAXON [VALSARTAN, AMLODIPINE, VALSARTAN, AMLODIPINE BESILATE]] (C - n/a - n/a - [n/a - n/a - n/a]), [ACETYSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [INSULIN, INSULIN HUMAN] (C - n/a - n/a - [n/a - n/a - Subcutaneous]), [LETROZOLE] (C - n/a - n/a - [n/a - n/a - n/a]), [LEVOTHYROXINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]), [METOPROLOL TARTRATE, METOPROLOL, TARTRATE BP] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000857248 | 11/08/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Headache (n/a - Unknown - CausedProlonged Hospitalisation), Pain (n/a - Unknown - CausedProlonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)] (S - n/a - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |

| EU Local Number | EV Category | Report Type | Primary Country | Primary Regulatory Authority | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form | |
|-------------------|-------------|-------------|-----------------------------|------------------------------|----------------------|--------------------|---------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| | | | | | | | | | Myocardial infarction (n/a - Fatal - Results in Death, Other Medically Important Condition), Peripheral swelling (n/a - Fatal - Results in Death), Respiratory disorder (n/a - Fatal - Results in Death), Visual impairment (n/a - Fatal - Results in Death) | | | | |
| EU-EC-1000919858 | 09/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000921628 | 09/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death), Language disorder (n/a - Not Recovered/Not Resolved -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000920259 | 09/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000928087 | 07/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Abdominal pain (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Blood creatinine increased (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Renal failure (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000928617 | 07/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Confusional state (2mo - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Dysphagia (2mo - Not Recovered/Not Resolved - Life Threatening, Other Medically Important Condition), Facial paralysis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Fatigue (1d - Recovered/Resolved -), Hemiplegia (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Motor dysfunction (2mo - Not Recovered/Not Resolved - Other Medically Important Condition), Prion disease (n/a - Unknown - Life Threatening), Speech disorder (2mo - Not Recovered/Not Resolved - Other Medically Important Condition), Tremor (n/a - Unknown -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | [METFORMIN, METFORMIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000928254 | 07/07/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [1d - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000927928 | 06/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000920278 | 03/07/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000925176 | 03/07/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Renal failure (n/a - Not Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [1d - n/a - n/a]) | [BUPRENORPHINE] (C - n/a - n/a - [n/a - 5mg - n/a]), [CARBIDOPA, LEVODOPA, LEVODOPA, ANHYDROUS CARBIDOPA, LEVODOPA, CARBIDOPA MONOHYDRATE] (C - n/a - n/a - [n/a - 100mg - n/a]), [COLECALCIFEROL] (C - n/a - n/a - [n/a - 80µg] - n/a), [FLUDCORTISONE] (C - n/a - n/a - [n/a - 1mg - n/a]), [SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [SUAVASIN, WAFERAN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]), [LXANA (DOXABAN, EDOKABAN TOSYLATE)] (C - n/a - n/a - [n/a - n/a - n/a]), [NUTRITIONAL SUPPLEMENT (NOT AVAILABLE)] (C - n/a - n/a - [n/a - n/a - n/a]), [CASIRIA] (C - n/a - n/a - [n/a - n/a - n/a]), [CHLORAMPHENICOL] (C - n/a - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]), [SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000925253 | 03/07/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Debilitating, Other Medically Important Condition), Decreased appetite (n/a - Unknown - Results in Death, Debilitating, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [1d - n/a - n/a]) | [SUAVASIN, WAFERAN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]), [LXANA (DOXABAN, EDOKABAN TOSYLATE)] (C - n/a - n/a - [n/a - n/a - n/a]), [NUTRITIONAL SUPPLEMENT (NOT AVAILABLE)] (C - n/a - n/a - [n/a - n/a - n/a]), [CASIRIA] (C - n/a - n/a - [n/a - n/a - n/a]), [CHLORAMPHENICOL] (C - n/a - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]), [SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000925232 | 03/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Confusional state (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Dizziness (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Dysphagia (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Dyspnoea (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Headache (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Nausea (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Pyrexia (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Tremor (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition), Vision blurred (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000925247 | 03/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000925143 | 03/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | No | Chest pain (n/a - Not Recovered/Not Resolved - Results in Death), Death (1d - Fatal - Results in Death), Dyspnoea (n/a - Not Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - n/a]) | [INSULIN HUMAN (INSULIN HUMAN)] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000925420 | 03/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000923732 | 02/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Headache (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000923295 | 02/07/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Cardiac arrest (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Cortisol (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Depressed level of consciousness (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Hypoaesthesia (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Pituitary (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Thrombotic thrombocytopenic purpura (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [1d - n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000924738 | 02/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Syncope (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000921618 | 01/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Blood creatinine increased (n/a - Unknown - Caused/Prolonged Hospitalisation), Blood pressure fluctuation (n/a - Unknown - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation), Fatigue (n/a - Unknown -), Headache (n/a - Unknown -), Heart rate increased (n/a - Unknown - Caused/Prolonged Hospitalisation), Pain (n/a - Unknown -), Pyrexia (n/a - Unknown -), Renal disorder (n/a - Unknown -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000924745 | 01/07/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Hemiplegia (n/a - Fatal - Results in Death), Chest pain (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Dysphagia (n/a - Fatal - Results in Death), Fatigue (n/a - Fatal - Results in Death), Myalgia (n/a - Fatal - Results in Death), Nausea (n/a - Fatal - Results in Death), Pneumonia (n/a - Fatal - Results in Death), Tremor (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000922783 | 01/07/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000929279 | 30/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 2 Months - 2 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Maternal exposure during breast feeding (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - Transmammary]) | Not reported | ICSR |
| EU-EC-1000929884 | 30/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000929574 | 30/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [n/a - 100mg - n/a]) | Not reported | ICSR |
| EU-EC-1000929983 | 30/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-10009210741 | 30/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (0d - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - 5mL - intramuscular]) | Not reported | ICSR |
| EU-EC-10009212511 | 30/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Fatigue (n/a - Unknown -), Hyperhidrosis (n/a - Unknown -), Loss of consciousness (n/a - Fatal - Results in Death), Pain (n/a - Unknown -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - Not applicable [n/a - 5mL - intramuscular]) | NOT AVAILABLE (C - n/a - Dose not changed -), [SYNARDY (METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN)] (C - n/a - Dose not changed -), [GABAPENTIN] (C - n/a - Dose not changed -), [INDAPAMIDE, AMLODIPINE BESILATE, PERINDOPRIL ARGININE] (C - n/a - Dose not changed -), [ROSLIVASTATIN, ROSUVASTATIN CALCIUM] (C - n/a - Dose not changed -), [COLFERISONE HYDROCHLORIDE] (C - n/a - Dose not changed -) | ICSR |
| EU-EC-1000918602 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Loss of consciousness (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Pyrexia (n/a - Unknown -) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000918631 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Apnoea (n/a - Fatal - Results in Death), Cardiac arrest (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000918679 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Headache (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000918959 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Circulatory collapse (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Fatigue (n/a - Unknown -) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000918979 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | No | Malaise (n/a - Unknown -) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000918949 | 29/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Brain injury (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Cerebral haemorrhage (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Central thrombosis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Dizziness (n/a - Unknown -), Malaise (n/a - Unknown -), Thrombosis (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1000918028 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000918032 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1000918076 | 29/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | No | Constipation (n/a - Unknown -), Death (5h - Fatal - Results in Death, Life Threatening, Other Medically Important Condition), Mouth haemorrhage (n/a - Unknown -) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [n/a - 100mg - intramuscular]) | [AMLODIPINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, AMLODIPINE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, AMLODIPINE HYDROCHLORIDE DIBYDRATE, HYDROCHLOROTHIAZIDE, ANHYDROUS AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a -), [AMLODIPINE, AMLODIPINE BESILATE] (C - n/a - n/a -), [BUCLOSONIDE, FORMOTEROL, FUMARATE DIBYDRATE, FORMOTEROL, FUMARATE, BUCLOSONIDE] (C - n/a - n/a -), [ETHYLENEDIAMINE, THEOPHYLLINE, THEOPHYLLINE] (C - n/a - n/a -), [PERINDOPRIL ARGININE] (C - n/a - n/a - [n/a - 5mg - n/a]) | ICSR |
| EU-EC-10009181967 | 29/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-10009177202 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Pyrexia (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-10009175136 | 29/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death), Fatigue (n/a - Not Recovered/Not Resolved -), Finger痛 (n/a - Not Recovered/Not Resolved -), Language disorder (n/a - Not Recovered/Not Resolved -) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-10009175286 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Chest pain (n/a - Fatal - Results in Death), Cough (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Pyrexia (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-10009175726 | 29/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Adult | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [1d - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-10009177596 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Male | No | Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable [1d - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-10009181163 | 29/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Bedridden (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | VAZVEVRIA [COVID-19 VACCINE ASTRAZENECA (CHADOXI NCOV-19)] (S - n/a - Not applicable [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-10009181358 | 29/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Loss of personal independence in daily activities | | | |

| EU Local Number | EY Category | Report Type | Primary Source Qualification | Primary Country Regulatory Approval | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Leading Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|-------------------|-------------|-------------|------------------------------|-------------------------------------|----------------------|--------------------|---------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| EU-EC-1000915873 | 26/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | (INSULIN, INSULIN HUMAN) (C - Diabetes mellitus - in-fatal - Results in Death) | ICSR |
| EU-EC-1000916039 | 26/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 18-64 Years | Not Specified | Male | Cardiac arrest (in-fatal - Results in Death), Death (in-fatal - Results in Death, Life Threatening, Other Medically Important Condition), Influenza like illness (in-fatal - Recovered/Resolved - Results in Death), Malaise (in-fatal - Recovered/Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000916039 | 26/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (in-fatal - Results in Death, Life Threatening, Other Medically Important Condition), C-reactive protein increased (in-fatal - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Corns (in-fatal - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (in-fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Decreased appetite (in-fatal - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Lethargy (in-fatal - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Lower respiratory tract infection (in-fatal - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Mobility decreased (in-fatal - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000916047 | 26/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death, Caused/Prolonged Hospitalisation), Delirium (in-fatal - Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation), Oxygen saturation decreased (in-fatal - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation), Peripheral swelling (in-fatal - Unknown - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | (PARACETAMOL) (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000916433 | 26/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death, Life Threatening, Other Medically Important Condition), Dementia (in-fatal - Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition), Syncope (in-fatal - Unknown - Results in Death, Life Threatening, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000916437 | 26/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Male | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000916472 | 26/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Female | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000916756 | 25/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Adult | Female | Death (in-fatal - Results in Death), Influenza like illness (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000912621 | 24/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death), Agitation (in-fatal - Unknown - Results in Death), Chills (in-fatal - Unknown - Results in Death), Communication disorder (in-fatal - Unknown - Results in Death), Death (in-fatal - Results in Death), Fall (in-fatal - Unknown - Results in Death), Malaise (in-fatal - Unknown - Results in Death), Mobility decreased (in-fatal - Unknown - Results in Death), Pneumonia (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | CLOPIDOGREL (CLOPIDOGREL, CLOPIDOGREL BESILATE) (C - Cardiovascular accident - in-fatal - Results in Death), SITAGLIPTIN (SITAGLIPTIN) (C - Type 2 diabetes mellitus - in-fatal - Results in Death), ATORVASTATIN (C - Type 2 diabetes mellitus - in-fatal - Results in Death), BISOPROLOL (BISOPROLOL, FLUMARATE, BISOPROLOL, HEMIFUMARATE) (C - Ventricular tachycardia - in-fatal - Results in Death), BUPROPION (BUPROPION HYDROCHLORIDE) (C - Type 2 diabetes mellitus - in-fatal - Results in Death), DIPYRIDOL (C - Dementia - in-fatal - Results in Death), FINASTERIDE (C - Prostate cancer - in-fatal - Results in Death), GLIMEPIRIDE (C - Type 2 diabetes mellitus - in-fatal - Results in Death), METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP (C - Type 2 diabetes mellitus - in-fatal - Results in Death), TAMUSULOSIN (TAMUSULOSIN HYDROCHLORIDE) (C - Prostate cancer - in-fatal - Results in Death) | ICSR |
| EU-EC-1000912552 | 24/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | COVID-19 (in-fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Death (in-fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000912736 | 24/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (in-fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000913822 | 24/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Female | General thrombosis (in-fatal - Unknown - Caused/Prolonged Hospitalisation), Death (in-fatal - Results in Death, Caused/Prolonged Hospitalisation), Decreased appetite (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000912928 | 23/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Cardiac arrest (in-fatal - Results in Death), Cardiovascular disorder (in-fatal - Results in Death), Cognitive impairment (in-fatal - Results in Death), Death (in-fatal - Results in Death), Infection (in-fatal - Results in Death), Vascular graft thrombosis (in-fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000910044 | 23/06/2021 | Spontaneous | Non-Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (in-fatal - Results in Death, Other Medically Important Condition), Intra-abdominal fluid collection (in-fatal - Results in Death, Other Medically Important Condition), Thrombosis (in-fatal - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000910472 | 22/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | COVID-19 (14d - Fatal - Results in Death), Cardiac failure (14d - Fatal - Results in Death), Cardio-respiratory arrest (14d - Fatal - Results in Death), Death (14d - Fatal - Results in Death), Depressed appetite (14d - Fatal - Results in Death), Dependence on oxygen therapy (14d - Fatal - Results in Death), Disturbance in social behaviour (14d - Fatal - Results in Death), Fasciitis (14d - Fatal - Results in Death), Fasciitis soft (14d - Fatal - Results in Death), General physical health deterioration (14d - Fatal - Results in Death), Pleural effusion (14d - Fatal - Results in Death), Somnolence (14d - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | CLOPIDOGREL 75 MG (CLOPIDOGREL, CLOPIDOGREL BESILATE) (C - in-fatal - Results in Death), NOT AVAILABLE (C - in-fatal - Results in Death), (ACETYSALICYLIC ACID) (C - in-fatal - Results in Death), (CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE POWDER FORM) (C - in-fatal - Results in Death), (NEXOPAN SODIUM) (C - in-fatal - Results in Death), (FURCISEME, FURCISEME SODIUM) (C - in-fatal - Results in Death), (LORAZEPAM) (C - in-fatal - Results in Death), (PANTOPRAZOLE, PANTOPRAZOLE SODIUM) (C - in-fatal - Results in Death), (PERINDOPRIL, ARGININE) (C - in-fatal - Results in Death), (PRAVASTATIN SODIUM) (C - in-fatal - Results in Death), (SODIUM VALPROATE) (C - in-fatal - Results in Death), (VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE) (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000910782 | 22/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (in-fatal - Results in Death), Pyrexia (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000910923 | 22/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Elderly | Acute respiratory failure (in-fatal - Results in Death, Other Medically Important Condition), Cardiovascular disorder (in-fatal - Results in Death, Other Medically Important Condition), Death (in-fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000908382 | 21/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death, Other Medically Important Condition), Thrombotic (in-fatal - Unknown - Other Medically Important Condition), Medication error (in-fatal - Unknown - Results in Death), Asthma (in-fatal - Unknown - Results in Death), Circulatory collapse (in-fatal - Not Recovered/Not Resolved - Other Medically Important Condition), Death (in-fatal - Results in Death), Off label use (in-fatal - Unknown - Results in Death), Peripheral swelling (in-fatal - Unknown - Results in Death), Product use issue (in-fatal - Unknown - Results in Death), Social avoidant behaviour (in-fatal - Unknown - Results in Death) | COMBIVATY [TOZINMERAN] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]), COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | ARXIBAN (ARXIBAN) (C - Anal fistula - in-fatal - Results in Death), BUMETANIDE (BUMETANIDE) (C - in-fatal - Results in Death), INSULIN ASPART (INSULIN ASPART) (C - in-fatal - Results in Death), MIRABEGRON (MIRABEGRON) (C - in-fatal - Results in Death), ATORVASTATIN (C - in-fatal - Results in Death), (BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL, HEMIFUMARATE) (C - in-fatal - Results in Death), (BUPRENORPHINE) (C - in-fatal - Results in Death), (COLECALCIFEROL) (C - in-fatal - Results in Death), (FERROUS GLUCONATE) (C - in-fatal - Results in Death), (LANSOPRAZOLE) (C - in-fatal - Results in Death), (MIBEFERINE) (C - in-fatal - Results in Death), (MIRTAZAPINE) (C - in-fatal - Results in Death), (NABUMETONE) (C - in-fatal - Results in Death), (SERTRALINE, SERTRALINE HYDROCHLORIDE) (C - in-fatal - Results in Death), (SODIUM HYDROGEN CARBONATE) (C - in-fatal - Results in Death), (TAMUSULOSIN, TAMUSULOSIN HYDROCHLORIDE) (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000908181 | 20/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Circulatory collapse (in-fatal - Unknown - Results in Death), Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000907555 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | High fever (in-fatal - Unknown - Other Medically Important Condition), Brain injury (in-fatal - Unknown - Other Medically Important Condition), Circulatory collapse (in-fatal - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Corns (in-fatal - Unknown - Other Medically Important Condition), Death (in-fatal - Results in Death), Dyspnoea (in-fatal - Unknown - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000907613 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | (INFLUENZA VIRUS) (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000907604 | 19/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Female | Cardiac arrest (in-fatal - Unknown - Results in Death, Life Threatening), Death (in-fatal - Results in Death, Life Threatening) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | DILTIAZEM SODIUM (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000907421 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Female | Death (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000907473 | 19/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (in-fatal - Results in Death), Malaise (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-10009078157 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Male | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000907555 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-10009079723 | 19/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death, Other Medically Important Condition), Dyspnoea (in-fatal - Recovered/Resolved - Results in Death, Other Medically Important Condition), Pleural count decreased (in-fatal - Unknown - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | ARXIBAN (ARXIBAN) (C - Anal fistula - in-fatal - Results in Death) | ICSR |
| EU-EC-1000907978 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (in-fatal - Results in Death), Nausea (in-fatal - Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | PREGABALIN (PREGABALIN) (C - in-fatal - Results in Death), BIVOXAN (BIVOXAN) (C - in-fatal - Results in Death), (ALENDRONATE SODIUM, ALENDRONIC ACID) (C - in-fatal - Results in Death), (AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE) (C - in-fatal - Results in Death), (CALCIUM CARBONATE, CHOLECALCIFEROL CONCENTRATE POWDER FORM, COLECALCIFEROL, CALCIUM CARBONATE) (C - in-fatal - Results in Death), (COMPRAXOL) (C - in-fatal - Results in Death), (SERTRALINE, SERTRALINE HYDROCHLORIDE) (C - in-fatal - Results in Death), (BIVASTATIN) (C - in-fatal - Results in Death), (THIAMINE) (C - in-fatal - Results in Death), (ZOPICLONE) (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000907842 | 19/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (in-fatal - Results in Death), Hypotension (in-fatal - Recovered/Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | (BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL, HEMIFUMARATE) (C - Anal fistula - in-fatal - Results in Death), (BUPRENORPHINE) (C - in-fatal - Results in Death), (LEVOTHYRONINE, LEVOTHYRONINE SODIUM) (C - Hypothyroidism - in-fatal - Results in Death) | ICSR |
| EU-EC-1000907862 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Not Specified | Confusional state (in-fatal - Not Recovered/Not Resolved - Results in Death), Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000907968 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | 18-64 Years | Not Specified | Not Specified | Death (in-fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000907928 | 19/06/2021 | Spontaneous | Non-Healthcare Professional | Non-European Economic Area | Not available | Not Specified | Not Specified | Male | Death (in-fatal - Results in Death), Foetal exposure during pregnancy (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | (FOLIC ACID) (C - Vitamin supplementation - in-fatal - Results in Death) | ICSR |
| EU-EC-1000906762 | 18/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | General infection (in-fatal - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (in-fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Embolism (in-fatal - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Fall (in-fatal - Unknown - Results in Death), Femur fracture (in-fatal - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Muscular weakness (in-fatal - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000906539 | 18/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (in-fatal - Results in Death), Malaise (in-fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | ELIQUIS 5 MG (ARXIBAN) (C - in-fatal - Results in Death), (BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL, HEMIFUMARATE) (C - in-fatal - Results in Death), (BUMETANIDE) (C - in-fatal - Results in Death), (COLECALCIFEROL) (C - in-fatal - Results in Death), (FOLIC ACID) (C - in-fatal - Results in Death), (SPRONOLACTONE, SPRONOLACTONE BP) (C - in-fatal - Results in Death) | ICSR |
| EU-EC-1000904728 | 17/06/2021 | Spontaneous | Non-Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Cerebral infarction (in-fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Corns (in-fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (in-fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000904975 | 17/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (in-fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (C - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | ICSR |
| EU-EC-1000903112 | 16/06/2021 | Spontaneous | Non-Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | Death (in-fatal - Results in Death), Medication error (in-fatal - Results in Death, Other Medically Important Condition) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000903894 | 16/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | 18-64 Years | Not Specified | Male | Product administered to patient of inappropriate age (in-fatal - Results in Death, Other Medically Important Condition), Cardio-respiratory arrest (in-fatal - Fatal - Results in Death, Other Medically Important Condition), Death (in-fatal - Results in Death, Other Medically Important Condition), Peripheral swelling (in-fatal - Results in Death), Pulmonary embolism (in-fatal - Results in Death, Other Medically Important Condition) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - in-fatal - Results in Death, Other Medically Important Condition) | Not reported | ICSR |
| EU-EC-10009026743 | 16/06/2021 | Spontaneous | Healthcare Professional | Non-European Economic Area | Not available | 18-64 Years | Not Specified | Male | Cardiac arrest (in-fatal - Fatal - Results in Death, Other Medically Important Condition), Death (in-fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - Unknown - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000903898 | 16/06/2021 | Spontaneous | Non-Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (in-fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [in-fatal - Results in Death]) | Not reported | ICSR |
| EU-EC-1000910823 | 15/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (in-fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable | | |

| EU Local Number | EV Category | Report Date | Report Type | Primary Country | Primary Regulatory Purpose | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|------------------|-------------|-------------|-----------------------------|----------------------------|----------------------------|----------------------|-------------------|---------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | | | | | | | | | | Somnolence (n/a - Unknown - Results in Death) | | <ul style="list-style-type: none"> BUPROFEN (BUPROFEN, BUPROFEN SODIUM) (C - n/a - n/a - [n/a - n/a - n/a]), (ACETYSALICYLIC ACID) (C - n/a - n/a - [n/a - 75mg - n/a]), (ATORVASTATIN) (C - n/a - n/a - [n/a - 40mg - n/a]), (BUPRENORPHINE) (C - n/a - n/a - [n/a - 7.5mg - n/a]), (CASIA) (C - n/a - n/a - [n/a - 7.5mg - n/a]), (COLECALCIFEROL) (C - n/a - n/a - [n/a - 1000U] - n/a), (DIAZEPAM) (C - n/a - n/a - [n/a - 2mg - n/a]), (MEMANTINE) (C - n/a - n/a - [n/a - 20mg - n/a]), (MIRTAZAPINE) (C - n/a - n/a - [n/a - 30mg - n/a]), (NIVASTATIN) (C - n/a - n/a - [n/a - n/a - n/a]), (PRAFETAMOL) (C - n/a - n/a - [n/a - 20mg - n/a]), (PARACETAMOL) (C - n/a - n/a - [n/a - 500mg - n/a]), (SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350) (C - n/a - n/a - [n/a - n/a - n/a]), (ZOPICLONE) (C - n/a - n/a - [n/a - 7.5mg - n/a]) | |
| EU-EC-100887917 | 03/06/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Adverse event following immunisation (n/a - Fatal - Results in Death), Bundle branch block left (n/a - Fatal - Results in Death), Chronic obstructive pulmonary disease (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Hypertension (n/a - Fatal - Results in Death), Hypertension (n/a - Fatal - Results in Death), Type 2 diabetes mellitus (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100886499 | 02/06/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | Not Specified | Not Specified | Male | No | COVID-19 (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Epistaxis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Hemoptysis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008861132 | 01/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008859583 | 01/06/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100885963 | 01/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - intramuscular]) | <ul style="list-style-type: none"> (AMLODIPINE, TELMSARTAN) (C - n/a - n/a - [n/a - 10DF] - n/a), (DIDAZEPAM, DIDAZEPAM MESILATE) (C - n/a - n/a - [n/a - 4mg - n/a]), (METFORMIN HYDROCHLORIDE) (C - n/a - n/a - [n/a - 1000mg - n/a]) | ICSR |
| EU-EC-100887354 | 01/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100887355 | 01/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - intramuscular]) | <ul style="list-style-type: none"> (AMTRIPRYLINE HYDROCHLORIDE) (C - n/a - Unknown - [n/a - 25DF] - n/a), (ATORVASTATIN) (C - n/a - Unknown - [n/a - 10DF] - n/a), (CARBAMAZEPINE) (C - n/a - Unknown - [n/a - 25DF] - n/a), (RAMIPRIL) (C - n/a - Unknown - [n/a - 15DF] - n/a), (PANTOPRAZOLE SODIUM SESQUIHYDRATE) (C - n/a - Unknown - [n/a - 10DF] - n/a), (PARACETAMOL) (C - n/a - Unknown - [n/a - 25DF] - n/a), (QUETIAPINE) (C - n/a - Unknown - [n/a - 10DF] - n/a), (TRAZODONE HYDROCHLORIDE) (C - n/a - Unknown - [n/a - 10DF] - n/a) | ICSR |
| EU-EC-100886013 | 01/06/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Cerebral venous thrombosis (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Lung disorder (n/a - Unknown -) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100886895 | 31/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Acute hepatic failure (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Hypoalbuminaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition), International normalised ratio increased (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Jaundice (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Lactic acidosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Multiple organ dysfunction syndrome (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Portal vein thrombosis (n/a - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - n/a - [n/a - 10DF] - intramuscular) | <ul style="list-style-type: none"> ELIQUIS (APIXIBAN) (C - n/a - n/a -), JAVLOR (VINFLUNINE VINFLUNINE DITARTRATE) (C - Bladder cancer - [n/a - 10DF] - Intravenous (not otherwise specified)) | ICSR |
| EU-EC-1008844955 | 31/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [14 - 15DF] - intramuscular) | Not reported | ICSR |
| EU-EC-1008834778 | 30/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Pneumothorax (n/a - Unknown - Caused/Prolonged Hospitalisation), Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100883317 | 29/05/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008814949 | 28/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [14 - 15DF] - intramuscular) | Not reported | ICSR |
| EU-EC-100881490 | 28/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Pneumonia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Pyrexia (n/a - Not Recovered/Not Resolved -) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008819107 | 28/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Not Recovered/Not Resolved - Results in Death), Loss of consciousness (n/a - Not Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Not applicable - [14 - n/a - n/a]) | <ul style="list-style-type: none"> (MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE) (C - Pain - n/a - [n/a - n/a - n/a]), (PARACETAMOL) (C - Discomfort - n/a - [n/a - n/a - n/a]), (NANHYDROUS LACTIC ACID SODIUM) (C - n/a - Unknown - [n/a - 10DF] - n/a), (DIAZEPAM) (C - n/a - Unknown - [n/a - 5DF] - n/a), (DICLOFENAC SODIUM) (C - n/a - Unknown - [n/a - 3DF] - n/a), (METFORMIN, METFORMIN HYDROCHLORIDE) (C - n/a - Unknown - [n/a - 10DF] - n/a), (PARACETAMOL) (C - Pain - Unknown - [n/a - 10DF] - n/a), (PHENAZOPYRIDINE HYDROCHLORIDE) (C - n/a - Unknown - [n/a - 6DF] - n/a), (SULFAMETHOXAZOLE, TRIMETHOPRIM) (C - n/a - Unknown - [n/a - 2DF] - n/a), (TRAMADOL HYDROCHLORIDE) (C - n/a - Unknown - [n/a - 10DF] - n/a) | ICSR |
| EU-EC-100881967 | 28/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Agitation (100 - Fatal - Results in Death), Altered state of consciousness (100 - Fatal - Results in Death), Axillary vein thrombosis (100 - Fatal - Results in Death), Brain abscess (100 - Fatal - Results in Death), Brain empyema (100 - Fatal - Results in Death), Cavernous sinus thrombosis (100 - Fatal - Results in Death), Coagulopathy (100 - Fatal - Results in Death), Confusional state (100 - Fatal - Results in Death), Conjunctivitis (100 - Fatal - Results in Death), Death (100 - Fatal - Results in Death), Delirium (100 - Fatal - Results in Death), Dizziness (100 - Fatal - Results in Death), Eye oedema (100 - Fatal - Results in Death), Hypersensitivity (100 - Fatal - Results in Death), Jugular vein thrombosis (100 - Fatal - Results in Death), Meningitis bacterial (100 - Fatal - Results in Death), Nervous system disorder (100 - Fatal - Results in Death), Sinusitis (100 - Fatal - Results in Death), Subclavian vein thrombosis (100 - Fatal - Results in Death), Transverse sinus thrombosis (100 - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100881969 | 28/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Vaccination site reaction (n/a - Unknown - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - 5mL - intramuscular]) | Not reported | ICSR |
| EU-EC-1008834362 | 28/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | COVID-19 (n/a - Unknown - Caused/Prolonged Hospitalisation), Cerebrovascular accident (n/a - Unknown - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - Not applicable - [n/a - n/a - intramuscular]) | <ul style="list-style-type: none"> (CIMEZARTAN MEDOXOMIL, HYDROCHLOROTHIAZIDE) (C - n/a - Not applicable - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100879854 | 27/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation), General physical health deterioration (n/a - Unknown - Caused/Prolonged Hospitalisation), Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008790614 | 26/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100879016 | 26/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Cerebral haemorrhage (n/a - Fatal - Results in Death), Coagulopathy (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Thrombocytopenia (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008790617 | 26/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Cerebral haemorrhage (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Feeling abnormal (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100877312 | 25/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Headache (n/a - Fatal - Results in Death), Cough (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Other Medically Important Condition), Nasopharyngitis (n/a - Unknown - Other Medically Important Condition), Pyrexia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100877554 | 25/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - n/a - [n/a - n/a - intramuscular]) | <ul style="list-style-type: none"> ELIXA (BEMANTANE HYDROCHLORIDE) (C - n/a - n/a - [n/a - n/a - n/a]), FLAVIN (ELFDIOUREL, CLOFEDROGEL, HYDROGEN SULFATE) (C - n/a - n/a - [n/a - n/a - n/a]), (ATORVASTATIN) (C - n/a - n/a - [n/a - n/a - n/a]), (BROMAZEPAM) (C - n/a - n/a - [n/a - n/a - n/a]), (LANSOPRAZOLE) (C - n/a - n/a - [n/a - n/a - n/a]), (MIRTAZAPINE) (C - n/a - n/a - [n/a - n/a - n/a]), (QUETIAPINE) (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100877478 | 25/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100877496 | 25/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | No | Death (n/a - Fatal - Results in Death), Drug ineffective (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-100877445 | 25/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Epistaxis (n/a - Not Recovered/Not Resolved -), Headache (n/a - Not Recovered/Not Resolved -), Injection site pain (n/a - Not Recovered/Not Resolved -) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100878318 | 24/05/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Adverse event following immunisation (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | <ul style="list-style-type: none"> (AMTRIPRYLINE HYDROCHLORIDE) (C - n/a - n/a - [n/a - n/a - n/a]), (BUPRENORPHINE HYDROCHLORIDE) (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1008780740 | 24/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Transient ischaemic attack (n/a - Unknown - Other Medically Important Condition) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008743708 | 23/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Chest pain (n/a - Unknown - Results in Death), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Results in Death), Malaise (n/a - Unknown - Results in Death), Thrombosis (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008745202 | 23/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - n/a]) | <ul style="list-style-type: none"> (FUROSEMIDE) (C - Hypertension - n/a - [n/a - n/a - n/a]), (MORPHINE, MORPHINE HYDROCHLORIDE) (C - Pain - n/a - [n/a - n/a - n/a]), (PARACETAMOL DC) (C - Pain - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1008748719 | 22/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Balano disorder (n/a - Unknown - Results in Death, Other Medically Important Condition), Dizziness (n/a - Unknown - Results in Death, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Labyrinthitis (n/a - Unknown - Results in Death, Other Medically Important Condition), Malaise (n/a - Unknown - Results in Death, Other Medically Important Condition), Migraine (n/a - Unknown - Results in Death, Other Medically Important Condition), Vomiting (n/a - Unknown - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100874969 | 22/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008750386 | 22/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Fatigue (n/a - Not Recovered/Not Resolved - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [14 - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008752711 | 22/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | No | Death (n/a - Fatal - Results in Death), Epistaxis (n/a - Not Recovered/Not Resolved -) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008752718 | 22/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Elderly | Female | No | Death (n/a - Fatal - Results in Death), Mouth haemorrhage (n/a - Not Recovered/Not Resolved -), Chest pain (n/a - Not Recovered/Not Resolved -) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008767806 | 21/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | VAXZEVIRIA [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | Not reported | ICSR |
| EU-EC-1008716559 | 20/05/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Dyspnoea (n/a - Unknown - Caused/Prolonged Hospitalisation), Pyrexia (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV019)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - intramuscular]) | Not reported | ICSR |

| EU Local Number | EY Category | Report Type | Primary Country | Primary Regulatory Authority | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form | |
|-------------------|-------------|-------------|-------------------------|------------------------------|----------------------|--------------------|-------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------|
| EU-EC-100871695 | 20/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (D1 - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - n/a - Not applicable - i/va - 5mL - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008698770 | 19/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Cough (i/va - Fatal - Results in Death, Other Medically Important Condition), Death (i/va - Fatal - Results in Death), Pneumonia (i/va - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-100876538 | 19/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (i/va - Fatal - Results in Death), Pyrexia (i/va - Not Recovered/Not Resolved -) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - 1DP] - Intramuscular) | Not reported | ICSR | |
| EU-EC-100876904 | 19/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death), Hypertension (i/va - Fatal - Results in Death), Oxygen saturation decreased (i/va - Fatal - Results in Death), Vomiting (i/va - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - Immunisation - Not applicable - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008692478 | 18/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008671040 | 17/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Male | No | Death (D1 - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - i/va - 5mL - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008674115 | 17/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death), Haematemesis (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008668387 | 15/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - i/va - n/a - n/a) | TRIMBOW (BECLOMETASONE DIPROPIONATE, GLYCOPYRROLUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE) (C - n/a - n/a - i/va - n/a - Respiratory (Inhalation)), (ACETYSALICYLIC ACID) (C - n/a - n/a - i/va - n/a - n/a), (ALLOPURINOL) (C - n/a - n/a - i/va - n/a - n/a), (AMLODIPINE MESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE) (C - n/a - n/a - i/va - n/a - n/a), (CARBOCISTEINE) (C - n/a - n/a - i/va - n/a - n/a), (POLYACRYLIC ACID) (C - n/a - n/a - i/va - n/a - n/a), (BOROHNE SULFATE) (C - n/a - n/a - i/va - n/a - n/a), (SALBUTAMOL, SALBUTAMOL SULFATE) (C - n/a - n/a - i/va - n/a - n/a), (SMIINSTATIN) (C - n/a - n/a - i/va - n/a - n/a), (THEOPHYLLINE, THEOPHYLLINE ANHYDROUS, THEOPHYLLINE MONOHYDRATE) (C - n/a - n/a - i/va - n/a - n/a), (VITAMIN D) (C - n/a - n/a - i/va - n/a - n/a) | ICSR | |
| EU-EC-1008661378 | 15/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Cardiac arrest (i/va - Unknown - Other Medically Important Condition), Death (i/va - Unknown - Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008661751 | 15/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Male | No | Death (i/va - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008647005 | 14/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-100862969 | 13/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (D1 - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - i/va - 1DP - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008636448 | 13/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | COVID-19 (i/va - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Death (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Sepsis (i/va - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - Immunisation - Not applicable - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008641382 | 13/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Cardiovascular accident (i/va - Unknown - Other Medically Important Condition), Chest pain (i/va - Unknown -), Death (i/va - Fatal - Results in Death), Loss of consciousness (i/va - Unknown -), Pain (i/va - Unknown -), Pyrexia (i/va - Unknown -) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008618627 | 12/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Female | No | Abdominal pain (i/va - Unknown -), Cardiac disorder (i/va - Unknown -), Cerebral haemorrhage (i/va - Unknown - Life Threatening, Other Medically Important Condition), Death (i/va - Fatal - Results in Death), Embolism (i/va - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Haemorrhage (i/va - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Intracranial pressure increased (i/va - Unknown - Life Threatening, Caused/Prolonged Hospitalisation), Mastitis (i/va - Unknown -), SARS-CoV-2 test positive (i/va - Unknown -), Thrombocytopenia (i/va - Unknown - Other Medically Important Condition) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - n/a - Unknown - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008621983 | 12/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008620161 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Cough (i/va - Fatal - Results in Death, Life Threatening), Death (i/va - Fatal - Results in Death, Life Threatening), Malaise (i/va - Fatal - Results in Death, Life Threatening), Pyrexia (i/va - Fatal - Results in Death, Life Threatening) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008608198 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death), Pyrexia (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008608224 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Elderly | Female | Cerebral haemorrhage (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Death (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Intracranial haemorrhage (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | (ACETYSALICYLIC ACID) (C - n/a - n/a -) | ICSR | |
| EU-EC-1008609502 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 0-1 Month | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008609891 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - n/a - n/a - i/va - 5mL - Intramuscular) | HYDROCORTISONE (10) (HYDROCORTISONE, (HYDROCORTISONE SODIUM SUCCINATE)) (C - n/a - n/a - i/va - 10mg - n/a), (ATORVASTATIN) (C - n/a - n/a - i/va - 20mg - n/a), (ENALAPRIL ENALAPRIL MALEATE) (C - n/a - n/a - i/va - 20mg - n/a), (LEVOTHYROXINE, LEVOTHYROXINE SODIUM) (C - n/a - n/a - i/va - 75mg - n/a), (NAPROXEN, NAPROXEN SODIUM) (C - n/a - n/a - i/va - 250mg - n/a), (POTASSIUM SODIUM MACROGOL 3350, CHLORIDE ION, HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350) (C - n/a - n/a - i/va - [DF] - n/a), (TESTOSTERONE UNDECANOATE) (C - n/a - n/a - i/va - n/a - n/a) | ICSR | |
| EU-EC-1008611563 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR |
| EU-EC-1008611587 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 19-64 Years | Elderly | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR |
| EU-EC-1008611831 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR |
| EU-EC-1008616880 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Female | No | Asthma (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Decreased appetite (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Dyspepsia (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Dyspnoea (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Nausea (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Palpitations (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Pyrexia (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Rash (i/va - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - Immunisation - Not applicable - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008616889 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Asthma (i/va - Unknown - Other Medically Important Condition), Death (i/va - Fatal - Results in Death, Other Medically Important Condition), Dyspepsia (i/va - Unknown - Other Medically Important Condition), Speech disorder (i/va - Unknown - Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - Immunisation - Not applicable - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008616791 | 11/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Female | No | Asthma (i/va - Unknown - Caused/Prolonged Hospitalisation), Death (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Pyrexia (i/va - Unknown - Caused/Prolonged Hospitalisation), Vomiting (i/va - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - Immunisation - Not applicable - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008608706 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Female | No | Death (i/va - Fatal - Results in Death, Other Medically Important Condition), Pyrexia (i/va - Unknown -) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - n/a - Unknown - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008609164 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - i/va - 5mL - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008609171 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - i/va - 5mL - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008609182 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (D1 - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - [1d - n/a - n/a] | HYDROCHLOROTHIAZIDE (C - n/a - n/a - i/va - 12.5mg - Oral), (LOSARTAN, LOSARTAN POTASSIUM) (C - n/a - n/a - i/va - 50mg - Oral) | ICSR | |
| EU-EC-1008609286 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death), Malaise (i/va - Fatal - Results in Death), Oligosuria (i/va - Fatal - Results in Death), Pyrexia (i/va - Fatal - Results in Death), Somnolence (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - i/va - n/a - n/a) | XARELTO (RIVAROXABAN) (C - Pulmonary embolism - Unknown - i/va - n/a - n/a), (VLENLAFAXINE HYDROCHLORIDE) (C - n/a - Unknown - i/va - n/a - n/a) | ICSR | |
| EU-EC-1008609283 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-10086094703 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Male | No | Abdominal pain (S1 - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Brain oedema (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Cardiomyopathy (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Cerebral haemorrhage (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Cerebral venous sinus thrombosis (D1 - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Death (i/va - Fatal - Results in Death), Disseminated intravascular coagulation (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Malaise (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Nausea (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Pyrexia (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Seizure (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Sepsis (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Subarachnoid haemorrhage (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Thrombocytopenia (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Transverse sinus thrombosis (i/va - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Vomiting (D1 - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - n/a - [1d - 5mL - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008609488 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Female | No | Vomiting (D1 - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - Not applicable - i/va - 5mL - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008609488 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death), Pulseless electrical activity (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008609488 | 10/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death), Headache (i/va - Unknown -) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008609420 | 08/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Cardiac arrest (i/va - Recovering/Resolving - Results in Death), Death (i/va - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - i/va - n/a - n/a) | (ACETYSALICYLIC ACID) (C - n/a - n/a - i/va - n/a - n/a), (ALLOPURINOL) (C - n/a - n/a - i/va - n/a - n/a), (ATORVASTATIN) (C - n/a - n/a - i/va - n/a - n/a), (FUROSEMIDE) (C - n/a - n/a - i/va - n/a - n/a), (LISINAPRIL, LISINAPRIL DIHYDRATE) (C - n/a - n/a - i/va - n/a - n/a), (NIFEDIPINE) (C - n/a - n/a - i/va - n/a - n/a) | ICSR | |
| EU-EC-1008609488 | 08/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Male | No | Confusional state (i/va - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (i/va - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Delirium (i/va - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Hemiparesis/depression (i/va - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Hypertension (i/va - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Hypothermia (i/va - Unknown - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Thrombocytopenia (i/va - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - n/a] | Not reported | ICSR | |
| EU-EC-1008609488 | 07/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (D1 - Fatal - Results in Death), Diarrhoea (D1 - Fatal - Results in Death), Dyspnoea (D1 - Fatal - Results in Death), Incorrect route of product administration (i/va - Fatal - Results in Death), Nausea (D1 - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - Immunisation - Not applicable - i/va - n/a - Intravenous (not otherwise specified)) | Not reported | ICSR | |
| EU-EC-1008609488 | 07/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Male | No | Death (i/va - Fatal - Results in Death), Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - i/va - n/a - Intramuscular) | Not reported | ICSR | |
| EU-EC-1008609488 | 07/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008609488 | 07/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Female | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008609488 | 07/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Male | No | Death (i/va - Fatal - Results in Death) | VAZEVRIA (COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - i/va - n/a - n/a) | Not reported | ICSR | |
| EU-EC-1008609488 | 06/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Female | No | C-reactive protein increased (i/va - Fatal - Results in Death), Death (i/va - Fatal - Results in Death), General physical health deterioration (i/va - Fatal - Results in Death), Inflammation (i/va - Fatal - Results in Death), Malaise (i/va - Fatal - Results in Death), Pyrexia (i/va - Fatal - Results in Death), Respiratory disorder (i/va - Fatal - Results in Death) | COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19) [COVID-19 VACCINE ASTRAZENECA (CHAD0X1 NCOV-19)] (S - COVID-19 immunisation - Not applicable - i/va - n/a - n/a) | (BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEM | | |

| EU Case Number | EV Category | Report Type | Primary Country | Primary Regulatory Authority | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|------------------|-------------|-------------|-----------------------------|------------------------------|----------------------|--------------------|---------------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| EU-EC-100850704 | 06/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Not Recovered/Not Resolved -), Haemoptysis (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - COVID-19 immunisation - Not applicable - [1d - 1DF] - Intramuscular | LERCANDIPINE, LERCANDIPINE HYDROCHLORIDE (C - n/a - n/a -), PERINDOPRIL, PERINDOPRIL TERZ-BUTYLAMINE (C - n/a - n/a -), LURAPRIDE (C - n/a - n/a -), ACETYSALICYLIC ACID, DL-LYSINE ACETYSALICYLATE (C - n/a - n/a -), GALOPROLOL (C - n/a - n/a -), ATORVASTATIN, ATORVASTATIN CALCIUM (C - n/a - n/a -), BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE, BISOPROLOL HEMIFUMARATE (C - n/a - n/a -), DRIED FERROUS SULFATE, FERROUS SULFATE, FERROUS SULFATE HYDRATE, FERROUS SULPHATE SESQUIHYDRATE (C - n/a - n/a -), ENALAPRIL MALEATE, LERCANDIPINE HYDROCHLORIDE, LERCANDIPINE HYDROCHLORIDE (C - n/a - n/a -), FOLIC ACID (C - n/a - n/a -) | ICSR |
| EU-EC-100850397 | 05/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | Aggression (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Immobility (n/a - Fatal - Results in Death), Mood swings (n/a - Fatal - Results in Death), Personality change (n/a - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - n/a - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008540756 | 05/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - n/a - n/a - [n/a - n/a - n/a]) | ATORVASTATIN, ATORVASTATIN CALCIUM (C - n/a - n/a - [n/a - 40mg - Oral]), CLOPIDOGREL (C - n/a - n/a - [n/a - 75mg - Oral]), FLEODIPINE (C - n/a - n/a - [n/a - 5mg - Oral]), AMLODIPINE, AMLODIPINE BESILATE (C - n/a - n/a - [n/a - 2.5mg - Oral]), BETAMETHASONE, BETAMETHASONE SODIUM PHOSPHATE (C - n/a - n/a - [n/a - 6mg - n/a]), BIPHEPRINE (C - n/a - n/a - [n/a - 10DF] - n/a), COSELEL, COSELEL ACETATE (C - n/a - n/a - [n/a - 10DF] - n/a), HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXTEL (C - n/a - n/a - [n/a - 10DF] - Oral), METOPROLOL TARTRATE (C - n/a - n/a - [n/a - 50mg - n/a]), WARFARIN SODIUM (C - n/a - n/a - [n/a - 7.5mg - Oral]), CANDESARTAN CILEXTEL (C - n/a - n/a - [n/a - n/a - Oral]) | ICSR |
| EU-EC-100854682 | 05/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - n/a - n/a - [n/a - n/a - n/a]) | AMLODIPINE, AMLODIPINE BESILATE (C - n/a - n/a - [n/a - 2.5mg - Oral]), BETAMETHASONE, BETAMETHASONE SODIUM PHOSPHATE (C - n/a - n/a - [n/a - 6mg - n/a]), BIPHEPRINE (C - n/a - n/a - [n/a - 10DF] - n/a), COSELEL, COSELEL ACETATE (C - n/a - n/a - [n/a - 10DF] - n/a), HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXTEL (C - n/a - n/a - [n/a - 10DF] - Oral), METOPROLOL TARTRATE (C - n/a - n/a - [n/a - 50mg - n/a]), WARFARIN SODIUM (C - n/a - n/a - [n/a - 7.5mg - Oral]), CANDESARTAN CILEXTEL (C - n/a - n/a - [n/a - n/a - Oral]) | ICSR |
| EU-EC-100854734 | 05/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - n/a - n/a - [n/a - n/a - n/a]) | ATORVASTATIN, ATORVASTATIN CALCIUM (C - n/a - n/a - [n/a - 40mg - Oral]), CLOPIDOGREL (C - n/a - n/a - [n/a - 75mg - Oral]), FLEODIPINE (C - n/a - n/a - [n/a - 5mg - Oral]), AMLODIPINE, AMLODIPINE BESILATE (C - n/a - n/a - [n/a - 2.5mg - Oral]), BETAMETHASONE, BETAMETHASONE SODIUM PHOSPHATE (C - n/a - n/a - [n/a - 6mg - n/a]), BIPHEPRINE (C - n/a - n/a - [n/a - 10DF] - n/a), COSELEL, COSELEL ACETATE (C - n/a - n/a - [n/a - 10DF] - n/a), HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXTEL (C - n/a - n/a - [n/a - 10DF] - Oral), METOPROLOL TARTRATE (C - n/a - n/a - [n/a - 50mg - n/a]), WARFARIN SODIUM (C - n/a - n/a - [n/a - 7.5mg - Oral]), CANDESARTAN CILEXTEL (C - n/a - n/a - [n/a - n/a - Oral]) | ICSR |
| EU-EC-1008523773 | 04/05/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (1d - Fatal - Results in Death), Thrombosis (1d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008528650 | 04/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Acute coronary syndrome (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Unknown - [n/a - n/a - Intramuscular] | Not reported | ICSR |
| EU-EC-100852990 | 04/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - COVID-19 immunisation - Not applicable - [1d - 1DF] - Intramuscular | Not reported | ICSR |
| EU-EC-100852984 | 04/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Female | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - COVID-19 immunisation - Not applicable - [1d - 1DF] - Intramuscular | Not reported | ICSR |
| EU-EC-100851367 | 03/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | Death (n/a - Fatal - Results in Death), Haemorrhage (n/a - Fatal - Results in Death, Other Medically Important Condition), Thrombocytopenia (n/a - Fatal - Results in Death, Life Threatening) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-1008513731 | 03/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | COVID-19 (n/a - Unknown - Caused/Not Reported Hospitalisation, Disability), Death (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation, Disability) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - Immunisation - Not applicable - [n/a - n/a - Intramuscular] | Not reported | ICSR |
| EU-EC-100851468 | 03/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Cardiac arrest (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Gait disturbance (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation), Hypotension (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation), Mildly decreased (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation), Parosmia (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Unknown - [n/a - n/a - Intramuscular] | ACETYSALICYLIC ACID, ASPIRIN BP (C - n/a - n/a - [n/a - n/a - n/a]), (AMODARONE, AMODARONE HYDROCHLORIDE) (C - n/a - n/a - [n/a - 200mg - n/a]), (FUROSEMIDE) (C - n/a - n/a - [n/a - n/a - n/a]), (METOPROLOL, METOPROLOL TARTRATE) (C - n/a - n/a - [n/a - n/a - n/a]), (RAMPRIL) (C - n/a - n/a - [n/a - n/a - n/a]), (ROSUVASTATIN, ROSUVASTATIN CALCIUM) (C - n/a - n/a - [n/a - n/a - n/a]), (SERTRALINE, SERTRALINE HYDROCHLORIDE) (C - n/a - n/a - [n/a - n/a - n/a]), (SPIRONOLACTONE) (C - n/a - n/a - [n/a - n/a - n/a]), (BIVAROXAN, BIVAROXAN) (C - n/a - n/a - [n/a - 20mg - n/a]), (ACETYSALICYLIC ACID, ASPIRIN BP) (C - n/a - n/a - [n/a - 100mg - n/a]), (AMODARONE, AMODARONE HYDROCHLORIDE) (C - n/a - n/a - [n/a - 200mg - n/a]), (FUROSEMIDE) (C - n/a - n/a - [n/a - 40mg - n/a]), (RAMPRIL) (C - n/a - n/a - [n/a - 3mg - n/a]), (ROSUVASTATIN, ROSUVASTATIN CALCIUM) (C - n/a - n/a - [n/a - 10mg - n/a]), (SERTRALINE, SERTRALINE HYDROCHLORIDE) (C - n/a - n/a - [n/a - 50mg - n/a]), (LORAZEPAM) (C - n/a - n/a - [n/a - n/a - n/a]), (NEBIVOLOL) (C - n/a - n/a - [n/a - n/a - n/a]), (OLMESARTAN MEDOXOMIL) (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100851832 | 03/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Anorexia (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Dysphagia (n/a - Fatal - Results in Death), Parosmia (n/a - Fatal - Results in Death), Urinary retention (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Unknown - [n/a - n/a - Intramuscular] | ACETYSALICYLIC ACID, ASPIRIN BP (C - n/a - n/a - [n/a - n/a - n/a]), (AMODARONE, AMODARONE HYDROCHLORIDE) (C - n/a - n/a - [n/a - 200mg - n/a]), (FUROSEMIDE) (C - n/a - n/a - [n/a - 40mg - n/a]), (RAMPRIL) (C - n/a - n/a - [n/a - 3mg - n/a]), (ROSUVASTATIN, ROSUVASTATIN CALCIUM) (C - n/a - n/a - [n/a - 10mg - n/a]), (SERTRALINE, SERTRALINE HYDROCHLORIDE) (C - n/a - n/a - [n/a - 50mg - n/a]), (LORAZEPAM) (C - n/a - n/a - [n/a - n/a - n/a]), (NEBIVOLOL) (C - n/a - n/a - [n/a - n/a - n/a]), (OLMESARTAN MEDOXOMIL) (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1008500979 | 01/05/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Asthma (0d - Fatal - Results in Death), Chest pain (0d - Fatal - Results in Death), Death (0d - Fatal - Results in Death), Fibrin D dimer increased (0d - Fatal - Results in Death), Myocardial infarction (0d - Fatal - Results in Death), Thrombocytopenia (0d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100849474 | 30/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Cerebrovascular accident (n/a - Unknown - Caused/Not Reported Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Not Reported Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - Immunisation - Not applicable - [n/a - n/a - Intramuscular] | Not reported | ICSR |
| EU-EC-100849911 | 30/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100847696 | 29/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | PRADAXA 150 MG (BIBACITRAN ETELATE) (C - n/a - Unknown - [n/a - n/a - n/a]), (DILTIAZEM HYDROCHLORIDE) (C - n/a - Unknown - [n/a - n/a - n/a]), (FUROSEMIDE, FUROSEMIDE SODIUM) (C - n/a - Unknown - [n/a - n/a - n/a]), (METFORMIN HYDROCHLORIDE) (C - n/a - Unknown - [n/a - 10DF] - n/a), (PAROQUETINE, PAROQUETINE HYDROCHLORIDE HEMIHYDRATE) (C - n/a - Unknown - [n/a - n/a - n/a]), (ROSUVASTATIN CALCIUM) (C - n/a - Unknown - [n/a - n/a - n/a]), (SPIRONOLACTONE, SPIRONOLACTONE BP) (C - n/a - Unknown - [n/a - n/a - n/a]), (TRAZODONE HYDROCHLORIDE) (C - n/a - Unknown - [n/a - n/a - n/a]), (ACETYSALICYLIC ACID) (C - n/a - Unknown - [n/a - n/a - n/a]), (AMTRIPTYLINE, AMTRIPTYLINE HYDROCHLORIDE) (C - n/a - Unknown - [n/a - n/a - n/a]), (BENZERAZIDE HYDROCHLORIDE, LEVODOPA, BENSERAZIDE, LEVODOPA) (C - n/a - Unknown - [n/a - n/a - n/a]), (MICRONISED SPIRONOLACTONE, POTASSIUM CANRENOATE, SPIRONOLACTONE, SPIRONOLACTONE BP) (C - n/a - Unknown - [n/a - n/a - n/a]), (PARACETAMOL, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE) (C - n/a - Unknown - [n/a - n/a - n/a]), (ROSUVASTATIN) (C - n/a - Unknown - [n/a - n/a - n/a]), (TIMOLOL MALEATE) (C - n/a - Unknown - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100847963 | 28/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Cardiac arrest (1d - Fatal - Results in Death), Cardiovascular disorder (1d - Fatal - Results in Death), Cough (1d - Fatal - Results in Death), Fibrin D dimer increased (0d - Fatal - Results in Death), Myocardial infarction (0d - Fatal - Results in Death), Thrombocytopenia (0d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | ACETYSALICYLIC ACID) (C - n/a - Unknown - [n/a - n/a - n/a]), (AMTRIPTYLINE, AMTRIPTYLINE HYDROCHLORIDE) (C - n/a - Unknown - [n/a - n/a - n/a]), (BENZERAZIDE HYDROCHLORIDE, LEVODOPA, BENSERAZIDE, LEVODOPA) (C - n/a - Unknown - [n/a - n/a - n/a]), (MICRONISED SPIRONOLACTONE, POTASSIUM CANRENOATE, SPIRONOLACTONE, SPIRONOLACTONE BP) (C - n/a - Unknown - [n/a - n/a - n/a]), (PARACETAMOL, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE) (C - n/a - Unknown - [n/a - n/a - n/a]), (ROSUVASTATIN) (C - n/a - Unknown - [n/a - n/a - n/a]), (TIMOLOL MALEATE) (C - n/a - Unknown - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100847948 | 28/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - Immunisation - n/a - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-100848069 | 28/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 19-64 Years | Not Specified | Female | Asthma (0d - Fatal - Results in Death), COVID-19 (2d - Fatal - Results in Death), Death (0d - Fatal - Results in Death), Dyspnoea (0d - Fatal - Results in Death), Neopharyngitis (15d - Fatal - Results in Death), Pneumonia viral (2d - Fatal - Results in Death), Pyrexia (0d - Fatal - Results in Death), Respiratory failure (2d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - Immunisation - n/a - [n/a - 5mL - Intramuscular]) | FIGECORPIL SODIUM, HYDROCHLOROTHIAZIDE (C - Hypertensive heart disease - n/a - [n/a - n/a - Oral]), (BILIMONDI) (C - Hypertensive heart disease - n/a - [n/a - 1mg - Oral]) | ICSR |
| EU-EC-1008491363 | 27/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - Immunisation - n/a - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-1008484188 | 27/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Male | Death (1d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100848370 | 26/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (0d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - 5mL - Intramuscular]) | Not reported | ICSR |
| EU-EC-1008483028 | 26/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death), Vomiting (n/a - Unknown -) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Dizziness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Vomiting (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - n/a - n/a - [n/a - n/a - n/a]), (ATORVASTATIN) (C - Hypertension - n/a - [n/a - n/a - n/a]), (BENDROFLUMETHAZIDE) (C - n/a - n/a - [n/a - n/a - n/a]), (LEVOTHYROXINE, LEVOTHYROXINE SODIUM) (C - n/a - n/a - [n/a - n/a - n/a]), (RAMPRIL) (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1008483465 | 26/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | COVID-19 (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Not applicable - [1d - n/a - Intramuscular] | AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - n/a - n/a - [n/a - n/a - n/a]), (ATORVASTATIN) (C - Hypertension - n/a - [n/a - n/a - n/a]), (BENDROFLUMETHAZIDE) (C - n/a - n/a - [n/a - n/a - n/a]), (LEVOTHYROXINE, LEVOTHYROXINE SODIUM) (C - n/a - n/a - [n/a - n/a - n/a]), (RAMPRIL) (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1008483718 | 26/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - Immunisation - n/a - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-100842077 | 24/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-100842350 | 24/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 19-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-100841347 | 23/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Fatal - Results in Death, Other Medically Important Condition), Pulmonary embolism (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Not applicable - [n/a - n/a - Intramuscular] | ELIQUIS (APIXIBAN) (C - n/a - n/a - [n/a - n/a - n/a]), ACETYSALICYLIC ACID, ASPIRIN BP (C - n/a - n/a - [n/a - n/a - n/a]), (AMODARONE, AMODARONE HYDROCHLORIDE) (C - n/a - n/a - [n/a - n/a - n/a]), NOT AVAILABLE (C - n/a - n/a -), (ACETYSALICYLIC ACID) (C - n/a - n/a -), (METAZOLE, METAZOLE SODIUM, METAZOLE SODIUM MONOHYDRATE) (C - n/a - n/a -), (PANTOPRAZOLE, PANTOPRAZOLE SODIUM, METAZOLE SODIUM MONOHYDRATE) (C - n/a - n/a -), (FORASEMIDE) (C - n/a - n/a -) | ICSR |
| EU-EC-100839374 | 23/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | Acute pulmonary oedema (1d - Fatal - Results in Death), Cortic failure (1d - Fatal - Results in Death), Cardiovascular disorder (1d - Fatal - Results in Death), Chest pain (1d - Fatal - Results in Death), Death (1d - Fatal - Results in Death), Dizziness (1d - Fatal - Results in Death), Fall (1d - Fatal - Results in Death), Lactic acidosis (1d - Fatal - Results in Death), Respiratory distress (1d - Fatal - Results in Death), Tropoin T increased (1d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | NOT AVAILABLE (C - n/a - Unknown - [n/a - 1DF] - n/a), (AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE) (C - n/a - Unknown - [n/a - 1DF] - n/a), (BLYMERT) (C - n/a - Unknown - [n/a - n/a - n/a]), (GLYCERYL TRINITRATE) (C - n/a - Unknown - [n/a - 1DF] - n/a) | ICSR |
| EU-EC-1008403878 | 23/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Male | Death (1d - Fatal - Results in Death) | VAXEVRIA (COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)) (S - COVID-19 immunisation - Drug withdrawn - [1d - 5mL - Intramuscular]) | Not reported | ICSR |
| EU-EC-1008401616 | 22/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Headache (n/a - Not Recovered/Not Resolved -) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - Immunisation - n/a - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-100840346 | 22/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Abdominal pain upper (n/a - Unknown - Results in Death), Death (1d - Fatal - Results in Death), Hemiparesis (n/a - Recovered/Resolved - Results in Death), Vomiting (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - n/a - Not applicable - [n/a - n/a - n/a] | Not reported | ICSR |
| EU-EC-1008388621 | 21/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Elderly | Male | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCOV-19)] - COVID-19 immunisation - Not applicable - [1d - 1DF] - Intramuscular | Not reported | ICSR |
| EU-EC-1008389712 | 20/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Elderly | Male | Death (n/a - Fatal - Results in Death, Life Threatening),< | | | |

| EU Local Number | EY Category | Report Type | Primary Source | Primary Country | Literature Reference | Patient Age Group | Patient Sex | Patient Report | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|------------------|-------------|-------------|-----------------------------|----------------------------|----------------------|--------------------|---------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | | | | | | | | | Hematemesis (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition), Pulmonary embolism (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition), Unresponsive to stimuli (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition) | | BERTRALINE, SERTRALINE HYDROCHLORIDE (C - n/a - n/a - [n/a - 50mg - n/a]) | |
| EU-EC-100832086 | 17/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (14 - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Results in Death), Males (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | APRONID (KONG48012014) (HINDO-LIKE STRAIN (AHONG KONG48012014, K.308)), BRISBANE/60208-LIKE STRAIN (BRISBANE/60208, WLD TYPE), A CALIFORNIA/7208 (H1N1) (PMM)-DERIVED STRAIN USED IN VACC (BRISBANE/60208/2015, H1N1) (B), NPL/USA/2 VACCINE (C - Influenza immunisation - n/a - [n/a - n/a - n/a]), AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - Hypertension - n/a - [n/a - n/a - n/a]), CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE (C - Depression - n/a - [n/a - n/a - n/a]), LANSOPRAZOLE (C - Stomach - n/a - [n/a - n/a - n/a]), AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - Hypertension - n/a - [n/a - n/a - n/a]), CALCIUM CARBONATE (C - Osteopenia - n/a - [n/a - n/a - n/a]), CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE (C - Depressed mood - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100833089 | 17/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (23 - Fatal - Results in Death, Other Medically Important Condition), Lethargy (n/a - Unknown - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]) | AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - Hypertension - n/a - [n/a - n/a - n/a]), CALCIUM CARBONATE (C - Osteopenia - n/a - [n/a - n/a - n/a]), CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE (C - Depressed mood - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100833143 | 17/04/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 19-64 Years | Not Specified | Female | Pain in extremity (n/a - Unknown - Results in Death, Other Medically Important Condition), Angina pectoris (n/a - Unknown - Results in Death), Death (n/a - Fatal - Results in Death), Depressed mood (n/a - Unknown - Results in Death), Depression (n/a - Unknown - Results in Death), Dizziness (n/a - Unknown - Results in Death), Headache (n/a - Unknown - Results in Death), Hyperhidrosis (n/a - Unknown - Results in Death), Musculoskeletal chest pain (n/a - Unknown - Results in Death), Raynaud's phenomenon (n/a - Unknown - Results in Death), Seizure (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - n/a - n/a]) | AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - Hypertension - n/a - [n/a - n/a - n/a]), CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE (C - Depressed mood - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100833056 | 16/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Weight decreased (n/a - Unknown - Results in Death), Death (23 - Fatal - Results in Death), Embolus stroke (23 - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Injection site pain (23 - Recovered/Resolved -), Syncope (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | VAXZEVRIA (COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)) (S - Immunisation - Not applicable - [n/a - n/a - 2mL - Intramuscular]) | BISOPROLOL (C - Atrial fibrillation, Essential hypertension - Dose not changed - [n/a - 5mg - Oral]), CINNARIZINE, PRACETAMOL (C - Central anticholinergic - Dose not changed - [n/a - n/a - Oral]) | ICSR |
| EU-EC-100833373 | 16/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Chills (n/a - Not Recovered/Not Resolved -), Death (n/a - Fatal - Results in Death), Ischemia (n/a - Not Recovered/Not Resolved -), Pyrexia (n/a - Not Recovered/Not Resolved -) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100833383 | 16/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100831678 | 15/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Central artery thrombosis (2d - Fatal - Results in Death), Central infarction (2d - Fatal - Results in Death), Cerebrovascular accident (2d - Fatal - Results in Death), Death (2d - Fatal - Results in Death), Headache (1d - Fatal - Results in Death), Pain in extremity (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100831819 | 15/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Adult | Male | Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)) (S - COVID-19 immunisation - n/a - [1d - 1DF] - Intramuscular) | Not reported | ICSR |
| EU-EC-100831849 | 15/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Adult | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - 1DF] - Intramuscular) | Not reported | ICSR |
| EU-EC-100831838 | 15/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [1d - 1DF] - Intramuscular) | Not reported | ICSR |
| EU-EC-100830067 | 14/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (2d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Intramuscular]) | AFIDRA (INSULIN GLARGINE) (C - n/a - n/a - [n/a - 12U] - n/a), PRADAXA (DABIGATRAN ETEXILATE, DABIGATRAN ETEXILATE MESILATE) (C - n/a - n/a - [n/a - 150mg - n/a]), SIBIRINAZA (BRISQOLAMIDE, BRISQOLAMIDE TARTRATE) (C - n/a - n/a - [n/a - n/a - n/a]), ROUSOL (INSULIN GLARGINE) (C - n/a - n/a - [n/a - 30U] - n/a), BETAHISTINE DIHYDROCHLORIDE, BETAHISTINE DIHYDROCHLORIDE (C - n/a - n/a - [n/a - 2mg - n/a]), DORSOLAMIDE, TIMOLOL (C - n/a - n/a - [n/a - n/a - n/a]), FUROSEMIDE (C - n/a - n/a - [n/a - n/a - n/a]), METFORMIN HYDROCHLORIDE (C - n/a - n/a - [n/a - 1000mg - n/a]), PRACETAMOL (C - n/a - n/a - [n/a - 1200mg - n/a]), POTASSIUM CHLORIDE (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100828970 | 13/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (2d - Fatal - Results in Death), Decreased appetite (n/a - Not Recovered/Not Resolved -), Fatigue (n/a - Not Recovered/Not Resolved -), Headache (n/a - Not Recovered/Not Resolved -), Ischemic stroke (2d - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Males (n/a - Not Recovered/Not Resolved -), Musculoskeletal pain (n/a - Not Recovered/Not Resolved -), Pyrexia (n/a - Not Recovered/Not Resolved -), Syncope (2d - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | VAXZEVRIA (COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)) (S - Immunisation - Not applicable - [n/a - n/a - 2mL - Intramuscular]) | BISOPROLOL (C - n/a - Dose not changed -), PERINDOPRIL, TERT-BUTYLAMINE, AMLODIPINE BESILATE (C - Hypertension - Dose not changed - [n/a - n/a - Oral]), TORASEMIDE (C - n/a - Dose not changed -) | ICSR |
| EU-EC-100828133 | 13/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Adult | Female | Death (2d - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)) (S - COVID-19 immunisation - Not applicable - [n/a - 2mL - Intramuscular]) | INSULIN GLARGINE (INSULIN GLARGINE) (C - n/a - n/a - [n/a - n/a - Subcutaneous]), PREGABALIN (PREGABALIN) (C - n/a - n/a - [n/a - Oral]), SITAGLIPTIN (SITAGLIPTIN) (C - n/a - n/a - [n/a - 50mg - Oral]), AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - n/a - n/a - [n/a - n/a - Oral]), LORAZEPAM (C - n/a - n/a - [n/a - 20mg - Oral]), CANDESARTAN (C - n/a - n/a - [n/a - n/a - Oral]), EZZEMBE (C - n/a - n/a - [n/a - n/a - Oral]) | ICSR |
| EU-EC-100828294 | 13/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Adult | Female | Anaesthesia (n/a - Not Recovered/Not Resolved -), Brain oedema (n/a - Not Recovered/Not Resolved -), Cerebral venous sinus thrombosis (2d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Coma (n/a - Not Recovered/Not Resolved -), Death (2d - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation), Haemorrhage intracranial (n/a - Not Recovered/Not Resolved -), Hepatic artery thrombosis (1d - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation), Hepatic perfusion disorder (n/a - Not Recovered/Not Resolved -), Hepatic vein thrombosis (n/a - Not Recovered/Not Resolved -), Hypoferritinemia (n/a - Not Recovered/Not Resolved -), Immune thrombocytopenia (n/a - Not Recovered/Not Resolved -), Myeliasis (n/a - Not Recovered/Not Resolved -), Portal vein thrombosis (n/a - Not Recovered/Not Resolved -), Purple unequal (n/a - Not Recovered/Not Resolved -), Renal vein thrombosis (1d - Not Recovered/Not Resolved - Life Threatening, Caused/Prolonged Hospitalisation), Subarachnoid haemorrhage (n/a - Not Recovered/Not Resolved -) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100827402 | 12/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Mesenteric artery thrombosis (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100827814 | 12/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Thrombocytopenia (n/a - Fatal - Results in Death, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Dyspnoea (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Pyrexia (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - Not applicable - [n/a - n/a - Intramuscular]) | FUROSEMIDE (C - Product used for unknown indication - n/a -), LOSARTAN, LOSARTAN POTASSIUM (C - Product used for unknown indication - n/a -) | ICSR |
| EU-EC-100827705 | 12/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Female | COVID-19 (n/a - Not Recovered/Not Resolved -), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Not Recovered/Not Resolved -) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100827875 | 12/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Elderly | Female | Death (n/a - Fatal - Results in Death), Cerebrovascular accident (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | VAXZEVRIA (COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)) (S - n/a - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100827941 | 12/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100828159 | 12/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Tachycardia (n/a - Fatal - Results in Death, Other Medically Important Condition), Tachypnoea (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - n/a - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100827411 | 11/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Myocardial infarction (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | ACETYSALICYLIC ACID (C - Hypertension - n/a - [n/a - n/a - n/a]), AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE (C - n/a - n/a - [n/a - n/a - n/a]), BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE (C - n/a - n/a - [n/a - n/a - n/a]), CANDESARTAN (C - n/a - n/a - [n/a - n/a - n/a]), ROSUVASTATIN, ROSUVASTATIN CALCIUM (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100827428 | 11/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008281408 | 10/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Female | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODEINE PHOSPHATE (C - Pain - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100828201 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | LORAZEPAM (C - Sedation - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100828323 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100828474 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008285143 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death), Influenza like illness (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100828782 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | Death (4d - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Nausea (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation), Pyrexia (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation), Tumor (n/a - Unknown - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100827589 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100827596 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100827012 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (1d - Fatal - Results in Death), Hypoxic brain reaction (n/a - Recovered/Resolved - Results in Death), Pain in extremity (n/a - Recovered/Resolved - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100827010 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-1008272109 | 10/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Not Specified | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | Not reported | ICSR |
| EU-EC-100824204 | 09/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Blood fibrinogen decreased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Cerebrovascular accident (n/a - Not Recovered/Not Resolved - Life Threatening, Disabling, Other Medically Important Condition), Craniotomy (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Haematocrit decreased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Hemoglobin decreased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Heart rate increased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Hypotension (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Platelet count decreased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Platelet count increased (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Respiratory tract infection (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Thrombocytopenic purpura (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition), Thrombosis (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Disabling, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | EXFORDGE HCT 10 MG/160 MG/12.5 MG (VALSARTAN, AMLODIPINE, HYDROCHLOROTHIAZIDE, VALSARTAN, HYDROCHLOROTHIAZIDE, AMLODIPINE BESILATE) (C - n/a - n/a - [n/a - 1DF] - Oral), ACETYSALICYLIC ACID (C - n/a - n/a - [n/a - 100mg - Oral]), NEBUVLOL, NEBUVLOL HYDROCHLORIDE (C - n/a - n/a - [n/a - 1DF] - Oral), NEBUVLOL (C - n/a - n/a - [n/a - n/a - Oral]), POTASSIUM HYDROGEN CARBONATE, BETANE HYDROCHLORIDE, POTASSIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, BETANE HYDROCHLORIDE (C - n/a - n/a - [n/a - 1DF] - Oral), ROSUVASTATIN (C - n/a - n/a - [n/a - 10mg - Oral]) | ICSR |
| EU-EC-100824837 | 09/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death), Thrombosis (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation) | VAXZEVRIA (COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)) (S - n/a - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100825050 | 09/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (1d - Fatal - Results in Death, Other Medically Important Condition), Ventricular fibrillation (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100825167 | 09/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | Non Arthralgia (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Decreased appetite (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - Immunisation - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-100825196 | 09/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Fatal - Results in Death), Males (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZEMICA (CHADOXI NCOV-19)] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]) | NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]), PHARYNGOLIDE 50 MG - GASTRORESISTANT TABLET (C - n/a - n/a - [n/a - n/a - n/a]), COLICACICEROL (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100 | | | | | | | | | | | | |

| EU Local Number | EY Category | Report Type | Primary Source Qualification | Primary Country | Literature Reference | Patient Age Group | Patient Sex | Patient Status | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|------------------|-------------|-------------|------------------------------|----------------------------|-----------------------------------------------|--------------------|---------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| EU-EC-100824084 | 05/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | [BEMPARIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]), [DIOLOFENAC SODIUM] (C - Pain - n/a -), [ENALAPRIL ENALAPRIL MALEATE] (C - Hypertension - n/a - [n/a - 10mg - n/a]), [RAMPRIL] (C - Hypertension - n/a -), [VINPOCETINE] (C - Cerebrovascular accident - n/a -) | ICSR |
| EU-EC-100824167 | 05/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100824208 | 05/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (03 - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | [AMLODIPINE LISINAPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]), [BISOPROLOL FLUMARATE, BISOPROLOL FLUMARATE, ACETYSALICYLIC ACID, BISOPROLOL HEMIFUMARATE] (C - Hypertension - n/a - [n/a - 10mg - n/a]), [LANSOPRAZOLE] (C - Gastritis - n/a - [n/a - 30mg - n/a]), [RILMENIDINE, RILMENIDINE DIHYDROGEN PHOSPHATE] (C - Hypertension - n/a - [n/a - 1mg - n/a]), [ROSUVASTATIN] (C - Hyperlipaemia - n/a - [n/a - 40mg - n/a]), [ACELOFENAC] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100824206 | 05/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Bradycardia (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation), Cardiac arrest (04 - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Death (03 - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Resuscitation (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation), Syncope (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100821839 | 07/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Life Threatening) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100821930 | 07/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | [EDOXABAN] (C - n/a - n/a - [n/a - n/a - n/a]), [NCRUSE [MECLOXOLON BROMIDE]] (C - n/a - n/a - [n/a - n/a - n/a]), [PREGABALIN [PREGABALIN]] (C - n/a - n/a - [n/a - n/a - n/a]), [RILVAYR ELIFITRIFLUORACSONE FLURIDATE, VILANTEROL] (C - n/a - n/a - [n/a - n/a - n/a]), [SAMTROPYLINE, SAMTROPYLINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]), [FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]), [MORPHINE, MORPHINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [NEBIVOLOL] (C - n/a - n/a - [n/a - n/a - n/a]), [SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]), [TAMBULOSIN, TAMBULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [LEVITRACETAM [LEVITRACETAM]] (C - n/a - n/a - [n/a - 250mg - n/a]), [CARBOMER 990] (C - n/a - n/a - [n/a - n/a - n/a]), [COLICACIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]), [DOXUSATE] (C - n/a - n/a - [n/a - 100mg - n/a]), [FENTANYL] (C - n/a - n/a - [n/a - 1.2g - n/a]), [FOLIC ACID] (C - n/a - n/a - [n/a - 5mg - n/a]), [MIRTAZAPINE] (C - n/a - n/a - [n/a - 45mg - n/a]), [NITROFURANTON] (C - n/a - n/a - [n/a - 100mg - n/a]), [COMPRAXOLE] (C - n/a - n/a - [n/a - 20mg - n/a]), [PHENYTON SODIUM] (C - n/a - n/a - [n/a - 100mg - n/a]), [PREDNISOLONE] (C - n/a - n/a - [n/a - 1mg - n/a]), [PRIMIDONE] (C - n/a - n/a - [n/a - 250mg - n/a]) | ICSR |
| EU-EC-100821911 | 07/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Chills (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Decreased appetite (n/a - Unknown - Other Medically Important Condition), Dizziness (n/a - Unknown - Other Medically Important Condition), Hyperhidrosis (n/a - Unknown - Other Medically Important Condition), Left ventricular dilation (n/a - Unknown - Other Medically Important Condition), Loss of consciousness (n/a - Unknown - Other Medically Important Condition), Pain (n/a - Unknown - Other Medically Important Condition), Respiration abnormal (n/a - Unknown - Other Medically Important Condition), Tissue discoloration (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | [ENALAPRIL MALEATE] (C - Left ventricular dysfunction - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100821998 | 07/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Chest discomfort (n/a - Unknown - Life Threatening), Death (03 - Fatal - Results in Death, Life Threatening), Dyspnoea (n/a - Unknown - Life Threatening), Oxygen saturation decreased (n/a - Unknown - Life Threatening) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | [AMOXICILLIN, AMOXICILLIN TRIHYDRATE] (C - n/a - n/a - [n/a - 10ml - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]), [SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100821976 | 07/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100822179 | 07/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | NOT AVAILABLE (C - n/a - n/a - [n/a - n/a - n/a]), [LACTULOSE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1008231947 | 07/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Drug withdrawn - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100820628 | 05/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Asthma (n/a - Not Recovered/Not Resolved -), Death (n/a - Fatal - Results in Death), General physical health deterioration (n/a - Not Recovered/Not Resolved -), Pyrexia (n/a - Not Recovered/Not Resolved -) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100820871 | 05/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | [REPATH 140 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE [EVOLOCLUMAB]] (C - n/a - n/a - [n/a - n/a - n/a]), [ACETYSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]), [ALFUZOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - 10mg - n/a]), [BICALUTAMIDE] (C - n/a - n/a - [n/a - 150mg - n/a]), [BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 2.5mg - n/a]), [FINASTERIDE] (C - n/a - n/a - [n/a - 5mg - n/a]), [GLIPIZIDE] (C - n/a - n/a - [n/a - 2.5mg - n/a]), [GLYCEROL] (C - n/a - n/a - [n/a - n/a - n/a]), [HYDROCORTISONE BUTYRATE] (C - n/a - n/a - [n/a - n/a - n/a]), [METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - n/a - n/a - [n/a - 500mg - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - 1g - n/a]) | ICSR |
| EU-EC-100819263 | 03/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100817828 | 03/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100818026 | 03/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | Not Specified | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100818095 | 03/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100818447 | 03/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (1d - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - 5mg - n/a]), [DIONEPE] (C - n/a - n/a - [n/a - 10mg - n/a]), [LANSOPRAZOLE] (C - n/a - n/a - [n/a - 30mg - n/a]), [SERTRALINE, SERTRALINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - 150mg - n/a]) | ICSR |
| EU-EC-100818453 | 03/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Abdominal pain upper (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Appendicitis (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Fatigue (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Headache (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), High fever (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Patient count decreased (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Presyncope (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Purpura (n/a - Not Recovered/Not Resolved - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100818454 | 03/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | [ARXABAN [ARXABAN]] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]), [ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [BISOPROLOL, BISOPROLOL FLUMARATE, BISOPROLOL HEMIFUMARATE] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]), [DIGOXIN] (C - Atrial fibrillation - n/a - [n/a - n/a - n/a]), [FURSEMIDE] (C - Acute decompensation - n/a - [n/a - n/a - n/a]), [LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - Osteoarthritis - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100818613 | 03/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | Not Specified | Not Specified | Not Specified | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100818609 | 03/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - 5ml - Intravenous (not otherwise specified)]] | [SODIUM VALPROATE] (C - Epilepsy - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100818611 | 03/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Back pain (n/a - Not Recovered/Not Resolved - Results in Death), Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | BLOOD PRESSURE MEDICATION [NOT AVAILABLE] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100818635 | 03/04/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Back pain (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition), Dyspnoea (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition), Feeling hot (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition), Pain (n/a - Not Recovered/Not Resolved - Results in Death, Life Threatening, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | BLOOD PRESSURE MEDICATION [NOT AVAILABLE] (C - Hypertension - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100818904 | 03/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Chest discomfort (n/a - Unknown - Results in Death), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100819111 | 03/04/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100819035 | 02/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Asthma (n/a - Recovering/Resolved - Results in Death), Death (n/a - Fatal - Results in Death), Diarrhoea (1d - Recovered/Resolved - Results in Death), Pyrexia (1d - Recovered/Resolved - Results in Death), Vomiting (1d - Recovered/Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100817686 | 02/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (1d - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - 15DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100817418 | 02/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Drug withdrawn - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100817538 | 02/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (1d - Fatal - Results in Death), Thrombosis (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | [GLOPIDDRE, GLOPIDDRE, GLOPIDDRE BESILATE] (C - n/a - n/a - [n/a - n/a - n/a]), [ALENDRONATE SODIUM, ALENDRONIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]), [ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]), [CODINE] (C - n/a - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]), [FOLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100818038 | 01/04/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | Not Specified | Elderly | Male | Anaphylactic reaction (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100818747 | 01/04/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not reported, Not reported, Not reported, ... | 18-64 Years | Not Specified | Female | Chills (n/a - Unknown -), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation, Other Medically Important Condition), Headache (n/a - Unknown -), Meningitis (n/a - Unknown - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Nausea (n/a - Unknown -), Nervous system disorder (n/a - Unknown -), Pyrexia (n/a - Unknown -) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100814664 | 31/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Unknown - Results in Death), Hypertension (n/a - Unknown - Results in Death), Malaise (n/a - Unknown - Results in Death), Muscular weakness (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-100814894 | 31/03/2021 | Spontaneous | Non Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death), Loss of consciousness (n/a - Not Recovered/Not Resolved -) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-100814927 | 31/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Asthma (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Fall (n/a - Fatal - Results in Death), Resuscitation (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-1008191302 | 31/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Chills (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Fatal - Results in Death), Pneumonia (n/a - Fatal - Results in Death), Pyrexia (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | [NOVOMIR 30 FLIXEN [INSULIN ASPART, INSULIN ASPART, INSULIN ASPART PROTAMINE]] (C - n/a - n/a - [n/a - n/a - n/a]), [ACETYSALICYLIC ACID] (C - n/a - n/a - [n/a - 75mg - n/a]), [ATORVASTATIN] (C - n/a - n/a - [n/a - 40mg - n/a]), [CANDESARTAN CILEXETIL] (C - n/a - n/a - [n/a - 8mg - n/a]), [COLECALCIFEROL, CALCIUM] (C - n/a - n/a - [n/a - 10DF - n/a]), [CYANOCOBALAMIN] (C - n/a - n/a - [n/a - 1mg - n/a]), [FELODIPINE] (C - n/a - n/a - [n/a - 10mg - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - 60mg - n/a]), [PROPYLENE GLYCOL, PROPYLENE GLYCOL LACTIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-100815444 | 31/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Unknown - Other Medically Important Condition), Fatigue (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Pain (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - n/a - [n/a - n/a - n/a]] | Not reported | ICSR |
| EU-EC-1008133789 | 30/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - 10DF - Intramuscular]] | Not reported | ICSR |
| EU-EC-1008134171 | 30/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENEA (CHAD0X1 NCV0-19) [COVID-19 immunisation - Not applicable - [n/a - n/a - n/a]] | [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - n/a - n/a]), [HYDROXYZINE DIHYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - n/a - n/a - [n/a - n/a - n/a]), [BIPHROLOLACTONE] (C - Hypoaemia - n/a - [n/a - 10DF - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - 60mg - n/a]) | ICSR |

| EU Local Number | EY Summary Received Date | Report Type | Primary Source Qualification | Primary Country Regulatory Purpose | Literature Reference | Patient Age Group | Patient Sex (as reported) | Patient Race | Reaction List PT (Duration 7 Outcome - Seriousness Criteria) | Supporting/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form | |
|-------------------|--------------------------|-------------|------------------------------|------------------------------------|----------------------|--------------------|---------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|------|
| | | | | | | | | | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Dysphagia (n/a - Fatal - Results in Death, Other Medically Important Condition), Pyrexia (n/a - Fatal - Results in Death, Other Medically Important Condition), Death (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Disability, Other Medically Important Condition), Decreased appetite (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disability, Other Medically Important Condition), Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disability, Other Medically Important Condition) | | | | |
| EU-EC-1000793068 | 15/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death, Life Threatening, Caused/Prolonged Hospitalisation, Disability, Other Medically Important Condition), Decreased appetite (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disability, Other Medically Important Condition), Fatigue (n/a - Unknown - Life Threatening, Caused/Prolonged Hospitalisation, Disability, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | | ICSR | |
| EU-EC-1000791907 | 15/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Fatigue (n/a - Unknown - Other Medically Important Condition), Headache (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | MORPHINE SULFATE, MORPHINE SULFATE PENTAHYDRATE (C - Anesthetics - n/a - [n/a - n/a - n/a]), MORPHINE SULFATE, MORPHINE SULPHATE BP (C - Chem pain - n/a - [n/a - n/a - n/a]) | ICSR | |
| EU-EC-10007921975 | 14/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 85-95 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death, Life Threatening, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | APIXABAN (APIXABAN) (C - n/a - n/a - [n/a - n/a - n/a]), BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE (C - n/a - n/a - [n/a - n/a - n/a]), BUPROPION, BUPROPION HYDROCHLORIDE (C - n/a - n/a - [n/a - n/a - n/a]), METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP (C - n/a - n/a - [n/a - n/a - n/a]), PERINDOPRIL, PERINDOPRIL TERT-BUTYLAMINE (C - n/a - n/a - [n/a - n/a - n/a]), SIMVASTATIN (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR | |
| EU-EC-10007922008 | 14/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | CYCLOZINE TARTRATE, MORPHINE TARTRATE (C - Limb reduction defect - n/a - [n/a - n/a - intramuscular]), GABAPENTIN (C - Limb reduction defect - n/a - [n/a - n/a - n/a]), COXYCODONE HYDROCHLORIDE (C - Limb reduction defect - n/a - [n/a - n/a - n/a]), [TAPENTADOL, TAPENTADOL HYDROCHLORIDE] (C - Limb reduction defect - n/a - [n/a - n/a - n/a]), ZOLPIDEM, ZOLPIDEM TARTRATE (C - Insomnia - n/a - [n/a - n/a - n/a]), HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE SODIUM SUCCINATE (C - Addison's disease - n/a - [n/a - n/a - n/a]), [ACETYSALICYLIC ACID] (C - Prophylaxis - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL, CALCIUM CARBONATE] (C - Osteoporosis - n/a - [n/a - n/a - n/a]), [FLUDOCORTISONE] (C - Addison's disease - n/a - [n/a - n/a - n/a]), [CLOMIPRAZOLE] (C - Gastritis prophylaxis - n/a - [n/a - n/a - n/a]), [SIMVASTATIN] (C - Prophylaxis - n/a - [n/a - n/a - n/a]), [TRIMETHOPRIM] (C - Addison's disease - n/a - [n/a - n/a - n/a]), [GABAPENTIN] (C - Fentanyl - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007922014 | 14/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000792287 | 14/03/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | Chills (n/a - Unknown -), Death (n/a - Unknown -), Swelling (n/a - Recovered/Resolved -) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000792364 | 14/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Cardiac arrest (n/a - Unknown - Results in Death), Death (n/a - Fatal - Results in Death), Syncope (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | [ACETYSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [CALCIUM CARBONATE] (C - Asthma - n/a - [n/a - n/a - n/a]), [LACTULOSE] (C - Constipation - n/a - [n/a - n/a - n/a]), [MORPHINE, MORPHINE HYDROCHLORIDE] (C - Anesthetics - n/a - [n/a - n/a - n/a]) | ICSR | |
| EU-EC-10007924154 | 14/03/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death), Missile (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007925273 | 14/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | [AMTRIPTYLINE, AMTRIPTYLINE HYDROCHLORIDE] (C - Neuralgia - n/a - [n/a - n/a - n/a]), [DONPEZIL] (C - Dementia - n/a - [n/a - n/a - n/a]), [ESTRADIOL, ESTRADIOL HEMIHYDRATE] (C - Menopausal - n/a - [n/a - n/a - n/a]), [PROGESTERONE, PROGESTERONE, MICRONIZED] (C - Menopausal - n/a - [n/a - n/a - n/a]), [SIBIRINACA, SIBIRINACA, BRISODINONE TARTRATE] (C - n/a - n/a - [n/a - n/a - n/a]), [MAGNESIUM, MAGNESIUM TRISILICATE] (C - n/a - n/a - [n/a - n/a - 500mg - n/a]), [BENZERAZIDE, BENZERAZIDE, LEVODOPA] (C - n/a - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]), [FINASTERIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [FLUCLOXACILIN, FLUCLOXACILIN SODIUM, FLUCLOXACILIN SODIUM MONOHYDRATE] (C - n/a - n/a - [n/a - n/a - 500mg - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - 20mg - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - n/a - 40mg - n/a]), [LATANOPROST, TIMOLOL, TIMOLOL MALEATE, LATANOPROST] (C - n/a - n/a - [n/a - n/a - n/a]), [TAMBULOSIN, TAMBULOSIN HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [TRAMADOL, TRAMADOL HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [TRIPROFENIL, TRIPROFENIL ACETATE] (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007926948 | 14/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death), Lower respiratory tract infection (n/a - Not Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000792677 | 14/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | Body temperature increased (n/a - Recovered/Resolved -), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791839 | 13/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007919178 | 13/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791704 | 12/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | Acute kidney injury (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Bradycardia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Cerebral infarction (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Coma (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation), Death (n/a - Fatal - Results in Death, Caused/Prolonged Hospitalisation), Hypoglycaemia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Hypothermia (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation, Other Medically Important Condition), Hypothyroidism (n/a - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | | ICSR | |
| EU-EC-1000788752 | 11/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791428 | 10/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791917 | 10/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791730 | 09/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | | ICSR | |
| EU-EC-10007938811 | 07/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000794019 | 07/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000794024 | 07/03/2021 | Spontaneous | Non Healthcare Professional | Non European Economic Area | Not available | Not Specified | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000794293 | 07/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | 18-64 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death, Life Threatening) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007912679 | 06/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791276 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791272 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Elderly | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791281 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791286 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791282 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791306 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007913161 | 06/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791326 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007913261 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-1000791345 | 06/03/2021 | Spontaneous | Healthcare Professional | European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007913493 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007913510 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007913575 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007914477 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Elderly | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - n/a]) | | ICSR | |
| EU-EC-10007914539 | 06/03/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHADOXI NCOV-19)] (S - n/a - Unknown - [n/a - n/a - intramuscular]) | | ICSR | |

| EU Local Number | EY Category | Report Date | Report Type | Primary Source | Primary Country | Primary Regulatory Purpose | Literature Reference | Patient Age Group | Patient Sex | Patient Case Report | Reaction List (PT - Duration / Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|-------------------|-------------|-------------|-------------------------|----------------------------|-----------------|----------------------------|----------------------|-------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-----------|
| EU-EC-1000781589 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [LIGNOPRIL, LISINAPRIL, DILTIAZEM] (C - n/a - n/a - [n/a - 1DF] - n/a), [SIMVASTATIN] (C - n/a - n/a - [n/a - 1DF] - n/a), [TRIPROLENE, TRIPROLENE ACETATE] (C - n/a - n/a - [n/a - 1DF] - Intraocular) [ACEYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]) [ATORVASTATIN] (C - n/a - n/a - [n/a - n/a - n/a]) [FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]) [KANGONG KONG48012014 H2NG-LIKE STRAIN (AMONG KONG48012014, X.263B), BBRISBANE/60208-LIKE STRAIN (BBRISBANE/60208, WILD TYPE), A/CALFORMA/7209 (H1N1)P0M09 DERIVED STRAIN USED (NYMC) (SINGAPORE/EP1908/2015, YR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]) [CASSIA] (C - Constipation - n/a - [n/a - n/a - n/a]) [CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Panic attack - n/a - [n/a - n/a - n/a]) [DOCLUSATE SODIUM] (C - Constipation - n/a - [n/a - n/a - n/a]) [LORAZEPAM] (C - Pruritus - n/a - [n/a - n/a - n/a]) [DIPYRIZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]) [PROPANTELIN] (C - Salivary hyperecretion - n/a - [n/a - n/a - n/a]) [DIPLOLOLE] (C - Poor quality sleep - n/a - [n/a - n/a - n/a]) [ACEYLSALICYLIC ACID] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]) [AMOXICILIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]) [LEVOTHYROIDINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-1000781574 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [KANGONG KONG48012014 H2NG-LIKE STRAIN (AMONG KONG48012014, X.263B), BBRISBANE/60208-LIKE STRAIN (BBRISBANE/60208, WILD TYPE), A/CALFORMA/7209 (H1N1)P0M09 DERIVED STRAIN USED (NYMC) (SINGAPORE/EP1908/2015, YR-180), INFLUENZA VACCINE] (C - n/a - n/a - [n/a - n/a - n/a]) [CASSIA] (C - Constipation - n/a - [n/a - n/a - n/a]) [CITALOPRAM, CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROCHLORIDE] (C - Panic attack - n/a - [n/a - n/a - n/a]) [DOCLUSATE SODIUM] (C - Constipation - n/a - [n/a - n/a - n/a]) [LORAZEPAM] (C - Pruritus - n/a - [n/a - n/a - n/a]) [DIPYRIZOLE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]) [PROPANTELIN] (C - Salivary hyperecretion - n/a - [n/a - n/a - n/a]) [DIPLOLOLE] (C - Poor quality sleep - n/a - [n/a - n/a - n/a]) [ACEYLSALICYLIC ACID] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]) [AMOXICILIN SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]) [LEVOTHYROIDINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-1000781578 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death), Hypoxia (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [ACEYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 1DF] - n/a), [AMITRIPTYLINE HYDROCHLORIDE] (C - Bladder inton - n/a - [n/a - 2DF] - n/a), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [BETAMETHASONE VALERATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [BIZAFIRATIN] (C - Hypertension - n/a - [n/a - 1DF] - n/a), [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [CARBOCISTEINE] (C - n/a - n/a - [n/a - 750mg - n/a]), [CODAINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODAINE PHOSPHATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [CODAINE PHOSPHATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a - [n/a - 100mg - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - 2DF] - n/a), [INDAPAMIDE, INDAPAMIDE HEMHYDRATE] (C - Hypertension - n/a - [n/a - 1DF] - n/a), [LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - 1DF] - n/a), [MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 1DF] - n/a), [PARACETAMOL] (C - n/a - n/a - [n/a - 2DF] - n/a), [SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2DF] - Respiratory (inhalator)), [SPIRONOLACTONE] (C - n/a - n/a - [n/a - 1DF] - n/a), [TOTOPIRROL, TOTOPIRROL BROMIDE, TOTOPIRROL BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 1DF] - Respiratory (inhalator)) | | ICSR |
| EU-EC-1000781576 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Dehydration (n/a - Unknown - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-1000781591 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a] | [ACEYLSALICYLIC ACID] (C - n/a - n/a - [n/a - 1DF] - n/a), [AMITRIPTYLINE HYDROCHLORIDE] (C - Bladder inton - n/a - [n/a - 2DF] - n/a), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [BETAMETHASONE VALERATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [BIZAFIRATIN] (C - Hypertension - n/a - [n/a - 1DF] - n/a), [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [CARBOCISTEINE] (C - n/a - n/a - [n/a - 750mg - n/a]), [CODAINE PHOSPHATE BP, PARACETAMOL PH. EUR., PARACETAMOL, CODAINE PHOSPHATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [CODAINE PHOSPHATE] (C - n/a - n/a - [n/a - 1DF] - n/a), [DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a - [n/a - 100mg - n/a]), [FUROSEMIDE] (C - n/a - n/a - [n/a - 2DF] - n/a), [INDAPAMIDE, INDAPAMIDE HEMHYDRATE] (C - Hypertension - n/a - [n/a - 1DF] - n/a), [LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - 1DF] - n/a), [MONTELUKAST, MONTELUKAST SODIUM] (C - n/a - n/a - [n/a - 1DF] - n/a), [PARACETAMOL] (C - n/a - n/a - [n/a - 2DF] - n/a), [SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - 2DF] - Respiratory (inhalator)), [SPIRONOLACTONE] (C - n/a - n/a - [n/a - 1DF] - n/a), [TOTOPIRROL, TOTOPIRROL BROMIDE, TOTOPIRROL BROMIDE MONOHYDRATE] (C - n/a - n/a - [n/a - 1DF] - Respiratory (inhalator)) | | ICSR |
| EU-EC-1000781582 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Elderly | Male | No | Chest pain (n/a - Unknown - Results in Death), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-1000781746 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [DUQUIN, GENJUR (FORMOTEROL, FUMARATE DRYDRATE, ACLENIDUM BROMIDE)] (C - Chronic obstructive pulmonary disease - n/a - [n/a - n/a - n/a]), [INFLUENZA VIRUS] (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-1000781735 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Not Specified | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007818143 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [ACEYLSALICYLIC ACID] (C - n/a - n/a - [n/a - n/a - n/a]), [CHLORPHENIRAMINE] (C - n/a - n/a - [n/a - n/a - n/a]), [PRAZIPIRUM BROMIDE] (C - Dyspepsia - n/a - [n/a - n/a - n/a]), [LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]), [SALBUTAMOL, SALBUTAMOL SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007818799 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007818903 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [LEVOTHYROIDINE, LEVOTHYROIDINE SODIUM] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]), [SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]), [TEMAZEPAM] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]), [TRIMETHOPRIM] (C - Ill-defined disorder - n/a - [n/a - n/a - n/a]), [FERROUS FUMARATE] (C - Anaemia - n/a - [n/a - n/a - n/a]), [EMEPRAZOLE] (C - Malena - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007819560 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Elderly | Male | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007819565 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Life Threatening) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007819583 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [RIVASTIGMINE, RIVASTIGMINE, RIVASTIGMINE HYDROGEN TARTRATE] (C - Agitation - n/a - [n/a - n/a - n/a]), [CLONAZEPAM] (C - Agitation - n/a - [n/a - n/a - n/a]), [LEVOTHYROIDINE SODIUM] (C - Hypothyroidism - n/a - [n/a - n/a - n/a]), [FLUCLOXETINE, FLUCLOXETINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [LACTULOSE] (C - n/a - n/a - [n/a - n/a - n/a]), [LEVOTHYROIDINE, LEVOTHYROIDINE SODIUM] (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007819613 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death), Depressed level of consciousness (n/a - Not Recovered/Not Resolved - Results in Death), Malaise (n/a - Not Recovered/Not Resolved - Results in Death), Oxygen saturation decreased (n/a - Unknown - Results in Death), Unresponsive to stimuli (n/a - Not Recovered/Not Resolved - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [CARDIAC MEDICATION NOS] (NOT AVAILABLE) (C - n/a - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007819700 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - COVID-19 immunisation - Not applicable - [n/a - 1DF] - n/a] | Not reported | | ICSR |
| EU-EC-10007820612 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Debility) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [BUPIROPION, BUPROPION HYDROCHLORIDE] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]), [PANTOPRAZOL] (C - Pain - n/a - [n/a - n/a - n/a]), [FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]), [METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Diabetes mellitus - n/a - [n/a - n/a - n/a]), [EMEPRAZOLE] (C - Gastroesophageal reflux disease - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007821335 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007823879 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [ACEYLSALICYLIC ACID] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Coronary artery disease - n/a - [n/a - n/a - n/a]), [ATENOLOL, ATENOLOL BP] (C - Hypertension - n/a - [n/a - n/a - n/a]), [ROSUVASTATIN, ROSUVASTATIN CALCIUM] (C - Hyperlipidaemia - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007824893 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death, Life Threatening) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825001 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825002 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825003 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825004 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825006 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825008 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825011 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825014 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825029 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825043 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [DENOSUMAB (DENOSUMAB)] (C - n/a - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL] (C - n/a - n/a - [n/a - n/a - n/a]), [FEXOFENADINE, FEXOFENADINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [LANSOPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]), [LERCANIDIPINE, LERCANIDIPINE HYDROCHLORIDE] (C - n/a - n/a - [n/a - n/a - n/a]), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007825057 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death, Life Threatening, Debility) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Unknown - [n/a - n/a - n/a] | [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007825238 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Not applicable - [n/a - n/a - n/a] | Not reported | | ICSR |
| EU-EC-10007825241 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - n/a - Not applicable - [n/a - n/a - n/a] | [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]), [FERROUS SULFATE] (C - n/a - n/a - [n/a - n/a - n/a]), [EMEPRAZOLE] (C - Gastroesophageal reflux disease - n/a - [n/a - n/a - n/a]) | | ICSR |
| EU-EC-10007825250 | Spontaneous | 06/03/2021 | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCV0-19)] - COVID-19 immunisation - Dose not changed - [n/a - 500L - n/a] | [CLOPIDOGREL, CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]), [TIMOLOL] (C - Pan - n/a - [n/a - n/a - n/a]), [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a | | |

| EU Local Number | EV Gateway Receipt Date | Report Type | Primary Source Qualification | Primary Source Country | Primary Source Regulatory Region | Literature Reference | Patient Age Group | Patient Age (as reported) | Patient Sex | Patient Onset | Reaction List PT (Duration ? Outcome - Seriousness Criteria) | Suspect/Intending Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - Duration - Dose - Route) | ICSR Form |
|-------------------|-------------------------|-------------|------------------------------|----------------------------|----------------------------------|----------------------|-------------------|---------------------------|---------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| EU-EC-1000761364 | 18/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | Not available | Elderly | Not Specified | Male | No | Confusional state (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Urinary tract infection (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [A/NHONG KONG/401/2014 H3N2-LIKE STRAIN (A/NHONG KONG/401/2014, X-263B), B/BRISBANE/02/2009-LIKE STRAIN (B/BRISBANE/02/2009, WILD TYPE), A/CALIFORNIA/7/2009 (H1N1) PANDA-DERIVED STRAIN USED (NYMC 2-181), A/NHONG KONG/401/2014 H3N2-LIKE STRAIN (A/NHONG KONG/401/2014, X-263B), B/BRISBANE/02/2009-LIKE STRAIN (B/BRISBANE/02/2009, WILD TYPE), AMCHONGKANG/2015 (H1N1) PANDA-LIKE STRAIN (BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE) (C - n/a - n/a -), [CASIA] (C - Constipation - n/a -), [CETIRIZINE, CETIRIZINE DIIODIDE] (C - Hypersensitivity - n/a -), [FUROSEMIDE] (C - n/a - n/a -), [GLYCOPHYRROLUM] (C - n/a - n/a -), [LACTULOSE] (C - Constipation - n/a -), [LANSOPRAZOLE] (C - n/a - n/a -), [LORAZEPAM] (C - Anxiety - n/a -) | ICSR |
| EU-EC-1000762717 | 18/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death, Life Threatening), Sudden death (n/a - Unknown - Life Threatening) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [AMLODIPINE, AMLODIPINE BESILATE, AMLODIPINE MALEATE, AMLODIPINE MESILATE] (C - Hypertension - n/a - [n/a - n/a - n/a]), [ATENLOLOL, ATENOLOL, BP] (C - Hypertension - n/a - [n/a - n/a - n/a]), [ATORVASTATIN] (C - Atherosclerosis - n/a - [n/a - n/a - n/a]), [FINASTERIDE] (C - Prostatism - n/a - [n/a - n/a - n/a]), [ISOSORBIDE MONONITRATE] (C - Angina pectoris - n/a - [n/a - n/a - n/a]), [RAMIPRIL] (C - Hypertension - n/a - [n/a - n/a - n/a]), [SOLIFENACIN] (C - Prostatism - n/a - [n/a - n/a - n/a]), [CLOPIDOGREL, CLOPIDOGREL, CLOPIDOGREL BESILATE] (C - Myocardial ischaemia - n/a - [n/a - n/a - n/a]), [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Left ventricular failure - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-1000764047 | 17/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Pyrexia (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a -), [PARACETAMOL] (C - n/a - Unknown - [1d - n/a - Intramuscular]) | ICSR |
| EU-EC-1000764376 | 17/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | Not Specified | Elderly | Female | No | No | Cardiac failure (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a -), [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a -), [CASIA] (C - n/a - n/a -), [DIBIGOXIN] (C - n/a - n/a -), [FUROSEMIDE] (C - n/a - n/a -), [MACHOGOL, SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, MACROGOL 3350] (C - n/a - n/a -), [MIRTAZAPINE] (C - n/a - n/a -), [RAMIPRIL] (C - n/a - n/a -), [VITAMIN D] (C - n/a - n/a -) | ICSR |
| EU-EC-1000764729 | 17/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | No | Cardiac arrest (n/a - Fatal - Results in Death, Other Medically Important Condition), Chest pain (n/a - Fatal - Results in Death, Life Threatening), Death (n/a - Fatal - Results in Death), Dyspnoea (n/a - Fatal - Results in Death, Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [VITAMIN D] (C - n/a - n/a -) Not reported | ICSR |
| EU-EC-1000765388 | 16/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Female | No | No | Abdominal pain upper (n/a - Unknown - Debating), Death (n/a - Fatal - Results in Death, Debating), Illness (n/a - Recovering/Resolved - Debating), Migraine (n/a - Recovering/Resolved - Debating), Nervousness (n/a - Recovered/Resolved - Debating), Pain (n/a - Unknown - Debating), Purpura (n/a - Recovered/Resolved - Debating), Pyrexia (n/a - Recovered/Resolved - Debating), Swelling (n/a - Unknown - Debating), Tumor (n/a - Unknown - Debating), Vomiting (n/a - Unknown - Debating) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [1d - n/a - Intramuscular]) | [PARACETAMOL] (C - n/a - Unknown - [1d - n/a - Intramuscular]) | ICSR |
| EU-EC-1000761863 | 15/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death), Pyrexia (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [BIVASTROMINE, BIVASTROMINE HYDROGEN TARTRATE] (C - n/a - n/a -), [COLECALCIFEROL, CALCIUM] (C - n/a - n/a -), [FOLIC ACID] (C - n/a - n/a -), [NICOTINAMIDE, BIFOLAVIN, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE, NICOTINAMIDE, BIFOLAVIN, PYRIDOXINE HYDROCHLORIDE] (C - n/a - n/a -), [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a -), [MIRTAZAPINE] (C - n/a - n/a -), [RAMIPRIL] (C - n/a - n/a -), [THIAMINE HYDROCHLORIDE] (C - n/a - n/a -) | ICSR |
| EU-EC-10007619795 | 15/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | No | Cardiac arrest (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [BUMETANIDE, BUMETANIDE] (C - n/a - n/a -), [LINALGPTIN, LINALGPTIN] (C - n/a - n/a -), [ALLOPURINOL] (C - n/a - n/a -), [AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - n/a - n/a -), [ATORVASTATIN] (C - n/a - n/a -), [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a -), [CHENESARTAN] (C - n/a - n/a -), [COLECALCIFEROL] (C - n/a - n/a -), [EPLERENONE] (C - n/a - n/a -), [LANSOPRAZOLE] (C - n/a - n/a -), [RAMIPRIL] (C - n/a - n/a -) | ICSR |
| EU-EC-10007619797 | 15/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | No | Asthma (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]), [FUROSEMIDE] (C - Cardiac failure - n/a - [n/a - n/a - n/a]), [PERINDOPRIL, PERINDOPRIL TERZ-BUTYLAMINE] (C - Hypertension - n/a - [n/a - n/a - n/a]), [FAMBUSOLON, TAMBUSOLON HYDROCHLORIDE] (C - Prostatism - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10007622091 | 15/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | No | Breath sounds abnormal (n/a - Unknown - Life Threatening), Death (n/a - Fatal - Results in Death, Life Threatening), Somnolence (n/a - Unknown - Life Threatening) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [FAMBUSOLON, TAMBUSOLON HYDROCHLORIDE] (C - Prostatism - n/a - [n/a - n/a - n/a]), [CAMPRAZOLE] (C - n/a - n/a -), [CARMAMAZEPINE] (C - Epilepsy - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - n/a - n/a]), [FUROSEMIDE SODIUM] (C - Oedema - n/a - [n/a - n/a - n/a]), [LACTULOSE] (C - Constipation - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10007622617 | 15/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Not Specified | Not Specified | No | Aortic aneurysm (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [1d - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10007612344 | 14/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death, Other Medically Important Condition), Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10007608563 | 13/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 18-64 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death), Vomiting (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10007610129 | 13/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | No | Death (n/a - Fatal - Results in Death), Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Malaise (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [METFORMIN, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE BP] (C - Type 2 diabetes mellitus - n/a -) | ICSR |
| EU-EC-10007647271 | 10/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death), Nausea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Pneumonia (n/a - Fatal - Results in Death), Syncope (n/a - Unknown - Caused/Prolonged Hospitalisation) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10007658824 | 10/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | No | Balance disorder (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Death (n/a - Fatal - Results in Death), Headache (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Lethargy (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Pyrexia (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Somnolence (n/a - Not Recovered/Not Resolved - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Not applicable - [1d - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10007619526 | 10/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | No | Death (n/a - Fatal - Results in Death), Malaise (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19)] (S - n/a - Unknown - [n/a - n/a - Intramuscular]) | Not reported | ICSR |
| EU-EC-10007659218 | 09/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death), Malaise (n/a - Unknown - Other Medically Important Condition) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [MIRTAZAPINE] (C - Depression - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10007659219 | 09/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Male | No | No | Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [CLOPIDOGREL, CLOPIDOGREL, CLOPIDOGREL SULFATE] (C - n/a - n/a -), [AMIODARONE, AMIODARONE HYDROCHLORIDE] (C - Ventricular tachycardia - n/a -), [ATORVASTATIN] (C - n/a - n/a -), [BISOPROLOL, BISOPROLOL FUMARATE] (C - n/a - n/a -), [FUROSEMIDE] (C - n/a - n/a -), [PERINDOPRIL, PERINDOPRIL TERZ-BUTYLAMINE] (C - n/a - n/a -), [BICALUTAMIDE] (C - Prostate cancer - n/a - [n/a - n/a - n/a]), [CARMAMAZEPINE] (C - Epilepsy - n/a - [n/a - n/a - n/a]), [COLECALCIFEROL] (C - Vitamin D deficiency - n/a - [n/a - n/a - n/a]), [FUROSEMIDE SODIUM] (C - Oedema - n/a - [n/a - n/a - n/a]), [LACTULOSE] (C - Constipation - n/a - [n/a - n/a - n/a]), [PARACETAMOL] (C - Analgesic therapy - n/a - [n/a - n/a - n/a]) | ICSR |
| EU-EC-10007659705 | 09/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | More than 85 Years | Not Specified | Female | No | No | Cardiac failure (n/a - Unknown - Other Medically Important Condition), Death (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [S - n/a - Unknown - [n/a - n/a - Intramuscular]) | [BISACODYL] (C - n/a - n/a -), [COLECALCIFEROL, CALCIUM CARBONATE] (C - n/a - n/a -), [DOXYCYCLINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE] (C - n/a - n/a -), [FOLIC ACID] (C - n/a - n/a -), [LEVOTHYROXINE, LEVOTHYROXINE SODIUM] (C - n/a - n/a -), [MIRTAZAPINE] (C - n/a - n/a -), [MORPHINE SULFATE] (C - n/a - n/a -), [PARACETAMOL] (C - n/a - n/a -) | ICSR |
| EU-EC-10007604129 | 03/02/2021 | Spontaneous | Healthcare Professional | Non European Economic Area | Not available | 65-85 Years | Not Specified | Female | No | No | Chills (n/a - Fatal - Results in Death), Death (n/a - Fatal - Results in Death), Diarrhoea (n/a - Fatal - Results in Death), Dizziness (n/a - Fatal - Results in Death), Dyspnoea (n/a - Fatal - Results in Death), Headache (n/a - Fatal - Results in Death), Lymph node pain (n/a - Fatal - Results in Death), Myalgia (n/a - Fatal - Results in Death), Vomiting (n/a - Fatal - Results in Death) | COVID-19 VACCINE AZTRAZENACA (CHAD0X1 NCOV-19) [S - n/a - Not applicable - [1d - n/a - Intramuscular]) | [BISOPROLOL, BISOPROLOL FUMARATE, BISOPROLOL HEMIFUMARATE] (C - n/a - n/a - [n/a - n/a - n/a]), [LOSARTAN, LOSARTAN POTASSIUM] (C - n/a - n/a - [n/a - n/a - n/a]), [MEEBERVENE] (C - n/a - n/a - [n/a - n/a - n/a]), [CAMPRAZOLE] (C - n/a - n/a - [n/a - n/a - n/a]) | ICSR |